<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ALBENZA- albendazoleÂ tablet, film coatedÂ </strong><br><strong>ALBENZA- albendazoleÂ tablet, chewableÂ </strong><br>Amedra Pharmaceuticals LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer"><span class="Bold">These highlights do not include all the information needed to use ALBENZA<span class="Sup">Â®</span> safely and effectively.  See full prescribing information for ALBENZA.
			<br><br>ALBENZA<span class="Sup">Â®</span> (albendazole) tablets, for oral use  
			<br>ALBENZA<span class="Sup">Â®</span> (albendazole) chewable tablets, for oral use
			<br>Initial U.S. Approval: 1996
		</span></div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ALBENZA is an anthelmintic drug indicated for: </p>
<ul class="Disk">
<li>Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, <span class="Italics">Taenia solium</span>. (<a href="#LINK_bc09d56e-49b3-41f2-b679-751fb8094bf1">1.1</a>)</li>
<li>Treatment of cystic <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">hydatid disease</span> of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, <span class="Italics">Echinococcus granulosus</span>. (<a href="#LINK_9accd0fb-41e4-4259-8934-ed4ff67fe471">1.2</a>)</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Patients weighing 60 kg or greater, 400 mg twice daily; less than 60 kg, 15 mg/kg/day in divided doses twice daily (maximum total daily dose 800 mg). ALBENZA tablets and ALBENZA chewable tablets should be taken with food. (<a href="#LINK_14fb8aec-ca8c-4877-8b65-9ef7040a4362">2</a>) </p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">Hydatid disease</span>: 28-day cycle followed by 14-day albendazole-free interval for a total of 3 cycles. (<a href="#LINK_14fb8aec-ca8c-4877-8b65-9ef7040a4362">2</a>)</li>
<li>Neurocysticercosis: 8 to 30 days. (<a href="#LINK_14fb8aec-ca8c-4877-8b65-9ef7040a4362">2</a>)</li>
</ul>
<p class="Highlighta">See additional important information in the Full Prescribing Information. (<a href="#LINK_14fb8aec-ca8c-4877-8b65-9ef7040a4362">2</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disk">
<li>Tablet: 200 mg (<a href="#LINK_673a4bdc-62fe-49ba-8bca-fca714b1d1d8">3</a>)</li>
<li>Chewable Tablet: 200 mg (<a href="#LINK_673a4bdc-62fe-49ba-8bca-fca714b1d1d8">3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the benzimidazole class of compounds or any components of ALBENZA.   (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk">
<li>Bone Marrow Suppression: Fatalities have been reported due to bone marrow suppression; monitor blood counts in all patients at the beginning of each 28-day cycle of therapy, and every 2 weeks while on therapy. Discontinue ALBENZA if clinically significant changes in blood counts occur. (<a href="#LINK_8df6476b-155c-4fd9-b2ca-702f67f3665c">5.1</a>, <a href="#LINK_7f9f7ddb-9b74-4388-9f8e-377453f7a240">5.4</a>)</li>
<li>Teratogenic Effects: Obtain pregnancy test in women of reproductive potential prior to therapy and avoid usage in pregnant women except in clinical circumstances where no alternative management is appropriate. Discontinue therapy if pregnancy occurs and apprise patient of potential hazard to the fetus. (<a href="#LINK_e942328f-1ed8-4f31-b6c7-91030be265c8">5.2</a>)</li>
<li>Risk of <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic Symptoms</span>: Neurocysticercosis patients may experience cerebral <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">hypertensive episodes</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (<a href="#LINK_84f94a89-b2ce-4a57-8df2-a8658cb646b5">5.3</a>)</li>
<li>Risk of <span class="product-label-link" type="condition" conceptid="4188175" conceptname="Retinal damage">Retinal Damage</span> in Retinal <span class="product-label-link" type="condition" conceptid="201511" conceptname="Taenia saginata infection">Cysticercosis</span>: Cases of retinal involvement have been reported; examine the patient for the presence of retinal lesions before initiating therapy for neurocysticercosis. (<a href="#LINK_7f9f7ddb-9b74-4388-9f8e-377453f7a240">5.4</a>)</li>
<li>Hepatic Effects. Elevations of liver enzymes may occur. Monitor liver enzymes before the start of each treatment cycle and at least every 2 weeks while on ALBENZA therapy and discontinue if clinically significant elevations occur. (<a href="#LINK_3dcc9482-9a1c-4d3e-a6f1-4325e5e70732">5.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disk">
<li>Adverse reactions 1% or greater in <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">hydatid disease</span>: <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, reversible <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>/<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. (<a href="#LINK_d9044c5b-d44c-4acb-8fd7-9e584bc6fdb4">6.1</a>)</li>
<li>Adverse reactions 1% or greater in neurocysticercosis: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, raised intracranial pressure, meningeal signs. (<a href="#LINK_d9044c5b-d44c-4acb-8fd7-9e584bc6fdb4">6.1</a>)</li>
</ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Amedra Pharmaceuticals LLC at 1-888-894-6528 or FDA at 1-800-FDA-1088 or <span class="Italics"><span class="Underline">www.fda.gov/medwatch</span></span>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disk">
<li>Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when dexamethasone was coadministered with each dose of albendazole. (<a href="#LINK_53d73faf-5231-4db0-b24a-9ea76062c6d9">7.1</a>)</li>
<li>Praziquantel: In the fed state increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects. (<a href="#LINK_2994316b-8499-4d11-bed3-25eee73d2615">7.2</a>)</li>
<li>Cimetidine: Increased albendazole sulfoxide concentrations in bile and cystic fluid by about 2-fold in hydatid <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> patients. (<a href="#LINK_e61c6481-944c-40b6-9a7b-4598ab06b901">7.3</a>)</li>
<li>Theophylline: Albendazole induces cytochrome P450 1A in human <span class="product-label-link" type="condition" conceptid="4101758" conceptname="Hepatocellular carcinoma">hepatoma</span> cells; therefore, it is recommended that plasma concentrations of theophylline be monitored during and after treatment. (<a href="#LINK_3dcc9482-9a1c-4d3e-a6f1-4325e5e70732">5.5</a>, <a href="#LINK_55d1fb61-270e-4a34-a7cc-f6d5e694cf59">7.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 6/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Neurocysticercosis</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">Hydatid Disease</span></a></h2>
<h1><a href="#section-2" class="toc">2  DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosage</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Concomitant Medication to Avoid Adverse Reactions</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Monitoring for Safety Before and During Treatment</a></h2>
<h1><a href="#section-3" class="toc">3  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5  WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Bone Marrow Suppression</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Teratogenic Effects</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Risk of <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic Symptoms</span> in Neurocysticercosis</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Risk of <span class="product-label-link" type="condition" conceptid="4188175" conceptname="Retinal damage">Retinal Damage</span> in Patients with Retinal Neurocysticercosis</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Hepatic Effects</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Unmasking of Neurocysticercosis in Hydatid Patients</a></h2>
<h1><a href="#section-6" class="toc">6  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7  DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Dexamethasone</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Praziquantel</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Cimetidine</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Theophylline</a></h2>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1  Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4  Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5  Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 Patients with Extra-Hepatic Obstruction</a></h2>
<h1><a href="#section-9" class="toc">10  OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11  DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12  CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3  Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13  NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-13.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-13.2" class="toc">16.2 Storage and Handling</a></h2>
<h1><a href="#section-14" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_a091c424-131b-437a-a221-3339fe820d2c"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_bc09d56e-49b3-41f2-b679-751fb8094bf1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Neurocysticercosis</h2>
<p class="First">ALBENZA is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, <span class="Italics">Taenia solium</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9accd0fb-41e4-4259-8934-ed4ff67fe471"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">Hydatid Disease</span></h2>
<p class="First">ALBENZA is indicated for the treatment of cystic <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">hydatid disease</span> of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, <span class="Italics">Echinococcus granulosus</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_14fb8aec-ca8c-4877-8b65-9ef7040a4362"></a><a name="section-2"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_126079a4-1152-434c-99d8-60f82af111f8"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosage</h2>
<p class="First">Dosing of ALBENZA will vary depending upon the indication. ALBENZA tablets may be crushed or chewed and swallowed with a drink of water. ALBENZA chewable tablets are also available for children and patients who may experience swallowing difficulties. ALBENZA tablets and ALBENZA chewable tablets should be taken with food [<span class="Italics">see Clinical Pharmacology (<a href="#LINK_67620ac4-8428-47a8-a5b7-2f2aa441f910">12.3</a>)</span>].</p>
<table>
<caption><span>Table 1: ALBENZA Dosage</span></caption>
<col width="25%">
<col width="25%">
<col width="25%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">Â <span class="Bold">Indication</span>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â <span class="Bold">Patient Weight</span>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â <span class="Bold">Dose</span>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â <span class="Bold">Duration</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" rowspan="2" valign="top">Â <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">Hydatid Disease</span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â 60 kg or greater</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â 400 mg twice daily, with meals</td>
<td class="Lrule Rrule Toprule" rowspan="2" valign="top">Â 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â Less than 60 kg</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top">Â Neurocysticercosis</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â 60 kg or greater</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â 400 mg twice daily, with meals</td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2">Â 8 to 30 days</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">Â Less than 60 kg</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a2eaf6fc-9b7f-489b-9a88-f2fbd8ee7bb3"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Concomitant Medication to Avoid Adverse Reactions</h2>
<p class="First">Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy as required. Oral or intravenous corticosteroids should be considered to prevent cerebral <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">hypertensive episodes</span> during the first week of treatment [<span class="Italics">see Warnings and Precautions (<a href="#LINK_84f94a89-b2ce-4a57-8df2-a8658cb646b5">5.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d18363e9-f3b3-4e65-8fbf-5e56dfd8ba0d"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Monitoring for Safety Before and During Treatment</h2>
<ul class="Disk">
<li>Monitor blood counts at the beginning of each 28-day cycle of therapy, and every 2 weeks while on therapy with ALBENZA in all patients [<span class="Italics">see Warnings and Precautions (<a href="#LINK_8df6476b-155c-4fd9-b2ca-702f67f3665c">5.1</a>)</span>].</li>
<li>Monitor liver enzymes (transaminases) at the beginning of each 28-day cycle of therapy, and at least every 2 weeks during treatment with ALBENZA in all patients [<span class="Italics">see Warnings and Precautions (<a href="#LINK_3dcc9482-9a1c-4d3e-a6f1-4325e5e70732">5.5</a>)</span>].</li>
<li>Obtain a pregnancy test in women of reproductive potential prior to therapy [<span class="Italics">see Warnings and Precautions (<a href="#LINK_e942328f-1ed8-4f31-b6c7-91030be265c8">5.2</a>)</span>].</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_673a4bdc-62fe-49ba-8bca-fca714b1d1d8"></a><a name="section-3"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS</h1>
<ul class="Disk">
<li>Tablet: 200 mg</li>
<li>Chewable Tablet: 200 mg</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_e31d0550-9e66-4f57-b0be-57b820b9d5d0"></a><a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<p class="First">ALBENZA is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the benzimidazole class of compounds or any components of ALBENZA.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_aca4b7d5-2458-4752-994e-b4447b1606f2"></a><a name="section-5"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8df6476b-155c-4fd9-b2ca-702f67f3665c"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Bone Marrow Suppression</h2>
<p class="First">Fatalities associated with the use of ALBENZA have been reported due to <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> or <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> ALBENZA may cause bone marrow suppression, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>. Monitor blood counts at the beginning of each 28-day cycle of therapy, and every 2 weeks while on therapy with ALBENZA in all patients. Patients with liver disease and patients with hepatic <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">echinococcosis</span> are at increased risk for bone marrow suppression and warrant more frequent monitoring of blood counts. Discontinue ALBENZA if clinically significant decreases in blood cell counts occur.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_e942328f-1ed8-4f31-b6c7-91030be265c8"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Teratogenic Effects</h2>
<p class="First">ALBENZA may cause fetal harm and should not be used in pregnant women except in clinical circumstances where no alternative management is appropriate. Obtain pregnancy test prior to prescribing ALBENZA to women of reproductive potential. Advise women of reproductive potential to use effective birth control for the duration of ALBENZA therapy and for one month after end of therapy. Immediately discontinue ALBENZA if a patient becomes pregnant and apprise the patient of the potential hazard to the fetus [<span class="Italics">see Use in Specific Populations (<a href="#LINK_150a082c-35da-41c4-84e6-66b42ced3a07">8.1</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_84f94a89-b2ce-4a57-8df2-a8658cb646b5"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Risk of <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic Symptoms</span> in Neurocysticercosis</h2>
<p class="First">Patients being treated for neurocysticercosis should receive steroid and anticonvulsant therapy to prevent neurological symptoms (e.g. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> and focal signs) as a result of an <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammatory reaction</span> caused by <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of the parasite within the brain.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7f9f7ddb-9b74-4388-9f8e-377453f7a240"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Risk of <span class="product-label-link" type="condition" conceptid="4188175" conceptname="Retinal damage">Retinal Damage</span> in Patients with Retinal Neurocysticercosis</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="201511" conceptname="Taenia saginata infection">Cysticercosis</span> may involve the retina. Before initiating therapy for neurocysticercosis, examine the patient for the presence of retinal lesions. If such lesions are visualized, weigh the need for anticysticeral therapy against the possibility of <span class="product-label-link" type="condition" conceptid="4188175" conceptname="Retinal damage">retinal damage</span> resulting from inflammatory damage caused by ALBENZA-induced <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of the parasite.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3dcc9482-9a1c-4d3e-a6f1-4325e5e70732"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Hepatic Effects</h2>
<p class="First">In clinical trials, treatment with ALBENZA has been associated with mild to moderate elevations of hepatic enzymes in approximately 16% of patients. These elevations have generally returned to normal upon discontinuation of therapy. There have also been case reports of <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span> of uncertain causality and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> [<span class="Italics">see Adverse Reactions (<a href="#LINK_af91181c-2c03-4281-8c99-2b1d3dfd562b">6</a>)</span>].</p>
<p>Monitor liver enzymes (transaminases) before the start of each treatment cycle and at least every 2 weeks during treatment. If hepatic enzymes exceed twice the upper limit of normal, consideration should be given to discontinuing ALBENZA therapy based on individual patient circumstances. Restarting ALBENZA treatment in patients whose hepatic enzymes have normalized off treatment is an individual decision that should take into account the risk/benefit of further ALBENZA usage. Perform laboratory tests frequently if ALBENZA treatment is restarted.</p>
<p>Patients with elevated liver enzyme test results are at increased risk for hepatotoxicity and bone marrow suppression [<span class="Italics">see Warnings and Precautions (<a href="#LINK_8df6476b-155c-4fd9-b2ca-702f67f3665c">5.1</a>)</span>]. Discontinue therapy if liver enzymes are significantly increased or if clinically significant decreases in blood cell counts occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6a98109e-3ff8-4e9c-a0c9-2a3469b07b73"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Unmasking of Neurocysticercosis in Hydatid Patients</h2>
<p class="First">Undiagnosed neurocysticercosis may be uncovered in patients treated with ALBENZA for other conditions. Patients with epidemiologic factors who are at risk for neurocysticercosis should be evaluated prior to initiation of therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_af91181c-2c03-4281-8c99-2b1d3dfd562b"></a><a name="section-6"></a><p></p>
<h1>6  ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d9044c5b-d44c-4acb-8fd7-9e584bc6fdb4"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The adverse reaction profile of ALBENZA differs between <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">hydatid disease</span> and neurocysticercosis. Adverse reactions occurring with a frequency of 1% or greater in either disease are described in Table 2 below.</p>
<p>These symptoms were usually mild and resolved without treatment. Treatment discontinuations were predominantly due to <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (0.7%) or hepatic abnormalities (3.8% in <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">hydatid disease</span>). The following incidence reflects adverse reactions that were reported to be at least possibly or probably related to ALBENZA.</p>
<table>
<caption><span>Table 2: Adverse Reaction Incidence 1% or Greater in <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">Hydatid Disease</span> and Neurocysticercosis</span></caption>
<col width="34%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule">Â <span class="Bold">Adverse Reaction</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â <span class="Bold"><span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">Hydatid Disease</span></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â <span class="Bold">Neurocysticercosis</span>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="3">Â <span class="Bold">Gastrointestinal</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 6</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 6</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="3">Â <span class="Bold">General disorders and administration site conditions</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 0</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="3">Â <span class="Bold">Investigations</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Elevated Hepatic Enzymes</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 16</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â less than 1</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="3">Â <span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â less than 1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 11</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Meningeal Signs</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 0</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Raised Intracranial Pressure</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 0</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â less than 1</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="3">Â <span class="Bold">Skin and subcutaneous tissue disorders</span>
</td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule">Â Reversible <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 2</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â less than 1</td>
</tr>
</tbody>
</table>
<p>The following adverse events were observed at an incidence of less than 1%:</p>
<p><span class="Bold">Blood and Lymphatic System Disorders:</span> There have been reports of <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> [<span class="Italics">see Warnings and Precautions (<a href="#LINK_8df6476b-155c-4fd9-b2ca-702f67f3665c">5.1</a>)</span>].</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d50960c0-2214-4be6-84d4-2a552809af8b"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of ALBENZA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Bold">Blood and Lymphatic System Disorders:</span> <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic anemia</span>, bone marrow suppression, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>.</p>
<p><span class="Bold">General System Disorders:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>.</p>
<p><span class="Bold">Hepatobiliary Disorders:</span> Elevations of hepatic enzymes, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span>.</p>
<p><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>.</p>
<p><span class="Bold">Renal and Urinary Disorders:</span> <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span>.</p>
<p><span class="Bold">Skin and Subcutaneous Tissue Disorders:</span> <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_fa8f9806-4a9d-49b0-bc51-08602f9af925"></a><a name="section-7"></a><p></p>
<h1>7  DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_53d73faf-5231-4db0-b24a-9ea76062c6d9"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Dexamethasone</h2>
<p class="First">Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was co-administered with each dose of albendazole (15 mg/kg/day) in 8 neurocysticercosis patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2994316b-8499-4d11-bed3-25eee73d2615"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Praziquantel</h2>
<p class="First">In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n = 10) compared with a separate group of subjects (n = 6) given albendazole alone. Mean T<span class="Sub">max</span> and mean plasma elimination half-life of albendazole sulfoxide were unchanged. The pharmacokinetics of praziquantel were unchanged following co-administration with albendazole (400 mg).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e61c6481-944c-40b6-9a7b-4598ab06b901"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Cimetidine</h2>
<p class="First">Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> patients treated with cimetidine (10 mg/kg/day) (n = 7) compared with albendazole (20 mg/kg/day) alone (n = 12). Albendazole sulfoxide plasma concentrations were unchanged 4 hours after dosing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_55d1fb61-270e-4a34-a7cc-f6d5e694cf59"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Theophylline</h2>
<p class="First">Following a single dose of albendazole (400 mg), the pharmacokinetics of theophylline (aminophylline 5.8 mg/kg infused over 20 minutes) were unchanged. Albendazole induces cytochrome P450 1A in human <span class="product-label-link" type="condition" conceptid="4101758" conceptname="Hepatocellular carcinoma">hepatoma</span> cells; therefore, it is recommended that plasma concentrations of theophylline be monitored during and after treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_e5741945-51db-4516-be4a-8f7d31a66156"></a><a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_150a082c-35da-41c4-84e6-66b42ced3a07"></a><a name="section-8.1"></a><p></p>
<h2>8.1  Pregnancy</h2>
<p class="First">Pregnancy Category C.</p>
<p>There are no adequate and well-controlled studies of ALBENZA administration in pregnant women. ALBENZA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>ALBENZA should not be used in pregnant women except in clinical circumstances where no alternative management is appropriate. Obtain pregnancy test prior to prescribing ALBENZA to women of reproductive potential. Advise women of reproductive potential to use effective birth control for the duration of ALBENZA therapy and for one month after end of therapy. If a patient becomes pregnant while taking this drug, ALBENZA should be discontinued immediately. If pregnancy occurs while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
<p>ALBENZA has been shown to be teratogenic (to cause embryotoxicity and skeletal malformations) in pregnant rats and rabbits. The teratogenic response in the rat was shown at oral doses of 10 and 30 mg/kg/day (0.10 times and 0.32 times the recommended human dose based on body surface area in mg/m<span class="Sup">2</span>, respectively) during gestation days 6 to 15 and in pregnant rabbits at oral doses of 30 mg/kg/day (0.60 times the recommended human dose based on body surface area in mg/m<span class="Sup">2</span>) administered during gestation days 7 to 19. In the rabbit study, maternal toxicity (33% mortality) was noted at 30 mg/kg/day. In mice, no teratogenic effects were observed at oral doses up to 30 mg/kg/day (0.16 times the recommended human dose based on body surface area in mg/m<span class="Sup">2</span>), administered during gestation days 6 to 15.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_5d659832-f622-4723-ba6a-dec339ba9efd"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">ALBENZA is excreted in animal milk. It is not known whether it is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ALBENZA is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_348a0626-6db1-412a-b13a-c3532570cae1"></a><a name="section-8.3"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">Hydatid disease</span> is uncommon in infants and young children. In neurocysticercosis, the efficacy of ALBENZA in children appears to be similar to that in adults.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_afafad40-1186-42f6-966c-33cddef14250"></a><a name="section-8.4"></a><p></p>
<h2>8.5  Geriatric Use</h2>
<p class="First">In patients aged 65 and older with either <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">hydatid disease</span> or neurocysticercosis, there was insufficient data to determine whether the safety and effectiveness of ALBENZA is different from that of younger patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2f859a28-4c2a-425f-9592-159fbd2104d1"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">The pharmacokinetics of ALBENZA in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> has not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ec1108e8-e16d-49e4-973c-e03fb2b7fdf0"></a><a name="section-8.6"></a><p></p>
<h2>8.7 Patients with Extra-Hepatic Obstruction</h2>
<p class="First">In patients with evidence of extrahepatic obstruction (n = 5), the systemic availability of albendazole sulfoxide was increased, as indicated by a 2-fold increase in maximum serum concentration and a 7-fold increase in area under the curve. The rate of absorption/conversion and elimination of albendazole sulfoxide appeared to be prolonged with mean T<span class="Sub">max</span> and serum elimination half-life values of 10 hours and 31.7 hours, respectively. Plasma concentrations of parent ALBENZA were measurable in only 1 of 5 patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_71332cbf-35dc-4404-a378-b024a139743d"></a><a name="section-9"></a><p></p>
<h1>10  OVERDOSAGE</h1>
<p class="First">In case of overdosage, symptomatic therapy and general supportive measures are recommended.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_9dd9b620-b316-4bed-aeca-fcc0daee9afe"></a><a name="section-10"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First">ALBENZA (albendazole) is an orally administered anthelmintic drug. Chemically, it is methyl 5-(propylthio)-2-benzimidazolecarbamate. Its molecular formula is C<span class="Sub">12</span>H<span class="Sub">15</span>N<span class="Sub">3</span>O<span class="Sub">2</span>S. Its molecular weight is 265.34. It has the following chemical structure:</p>
<div class="Figure"><img alt="methyl 5-(propylthio)-2-benzimidazolecarbamate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e8941166-b77d-45aa-a6e8-04f1c0afd845&amp;name=albenza-tablets-1.jpg"></div>
<p>Albendazole is a white to yellowish powder. It is freely soluble in anhydrous formic acid and very slightly soluble in ether and in methylene chloride. Albendazole is practically insoluble in alcohol and in water.</p>
<p><span class="Bold">Tablets</span></p>
<p>Each white to off-white, circular, biconvex, bevel-edged film coated, TILTAB tablet is debossed with â€œapâ€? and â€œ550â€? and contains 200 mg of albendazole.</p>
<p>Inactive ingredients consist of: carnauba wax, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, sodium lauryl sulfate, sodium saccharin, sodium starch glycolate, and starch.</p>
<p><span class="Bold">Chewable Tablets</span></p>
<p>Each round, mottled pink, concave chewable tablet is debossed with â€œapâ€? above â€œ551â€? and contains 200 mg of albendazole.</p>
<p>Inactive ingredients consist of: lactose monohydrate, microcrystalline cellulose, D-mannitol, sodium starch glycolate, povidone, N-C Wild Berry Type Flavor, magnesium stearate, crospovidone, polyvinyl acetate, sucralose, colloidal silicone dioxide, sodium lauryl sulfate, D&amp;C Red #30/Helendon Pink Aluminum Lake.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_da3bfc87-2e05-4d75-a0a7-0becc600fed1"></a><a name="section-11"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_0b5ed440-1bc7-4b36-a291-6300191f6ec4"></a><a name="section-11.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First">ALBENZA (albendazole) is a synthetic, antihelminthic drug of the class benzimidazole [<span class="Italics">see Clinical Pharmacology (<a href="#LINK_4ab605ca-efc8-41e9-9875-d60c743af9ee">12.4</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_67620ac4-8428-47a8-a5b7-2f2aa441f910"></a><a name="section-11.2"></a><p></p>
<h2>12.3  Pharmacokinetics</h2>
<p class="First"><span class="Bold"><span class="Italics">Absorption</span></span></p>
<p>Albendazole is poorly absorbed from the gastrointestinal tract due to its low aqueous solubility. Albendazole concentrations are negligible or undetectable in plasma as it is rapidly converted to the sulfoxide metabolite prior to reaching the systemic circulation. The systemic anthelmintic activity has been attributed to the primary metabolite, albendazole sulfoxide. Oral bioavailability appears to be enhanced when albendazole is coadministered with a fatty meal (estimated fat content 40 grams) as evidenced by higher (up to 5-fold on average) plasma concentrations of albendazole sulfoxide as compared to the fasted state.</p>
<p>Maximal plasma concentrations of albendazole sulfoxide were achieved 2 hours to 5 hours after dosing and were on average 1310 ng/mL (range 460 ng/mL to 1580 ng/mL) following oral doses of albendazole (400 mg) in 6 <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">hydatid disease</span> patients, when administered with a fatty meal. Plasma concentrations of albendazole sulfoxide increased in a dose-proportional manner over the therapeutic dose range following ingestion of a high-fat meal (fat content 43.1 grams). The mean apparent terminal elimination half-life of albendazole sulfoxide ranged from 8 hours to 12 hours in 25 healthy subjects, as well as in 14 hydatid and 8 neurocysticercosis patients.</p>
<p>In a study conducted in 113 fed and 117 fasted healthy subjects, ALBENZA chewable tablets were bioequivalent to ALBENZA tablets following single 400 mg oral doses of albendazole. In this study, the average time to reach the maximal plasma concentrations of albendazole sulfoxide was 4.5 hours (range 2 to 10 hours) with a fatty meal (fat content 60 grams) and at 3 hours (range 1 to 5 hours) in the fasted state. Following administration of ALBENZA chewable tablets, average maximal plasma concentrations of albendazole sulfoxide  were 804 ng/mL (range 202 to 2244 ng/mL) and 218 ng/mL (range 54 to 592 ng/mL) in the fed and fasted states, respectively. The apparent elimination half-life of albendazole sulfoxide was comparable between ALBENZA chewable tablets and ALBENZA tablets when both were given either under fed or fasted conditions.</p>
<p>Following 4 weeks of treatment with albendazole (200 mg three times daily), 12 patientsâ€™ plasma concentrations of albendazole sulfoxide were approximately 20% lower than those observed during the first half of the treatment period, suggesting that albendazole may induce its own metabolism.</p>
<p><span class="Bold"><span class="Italics">Distribution</span></span></p>
<p>Albendazole sulfoxide is 70% bound to plasma protein and is widely distributed throughout the body; it has been detected in urine, bile, liver, <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> wall, <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> fluid, and cerebrospinal fluid (CSF). Concentrations in plasma were 3-fold to 10-fold and 2-fold to 4-fold higher than those simultaneously determined in <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> fluid and CSF, respectively.</p>
<p><span class="Bold"><span class="Italics">Metabolism and Excretion</span></span></p>
<p>Albendazole is rapidly converted in the liver to the primary metabolite, albendazole sulfoxide, which is further metabolized to albendazole sulfone and other primary oxidative metabolites that have been identified in human urine. Following oral administration, albendazole has not been detected in human urine. Urinary excretion of albendazole sulfoxide is a minor elimination pathway with less than 1% of the dose recovered in the urine. Biliary elimination presumably accounts for a portion of the elimination as evidenced by biliary concentrations of albendazole sulfoxide similar to those achieved in plasma.</p>
<p><span class="Bold"><span class="Italics">Specific Populations</span></span></p>
<p><span class="Bold"><span class="Italics">Pediatrics</span></span></p>
<p>Following single-dose administration of 200 mg to 300 mg (approximately 10 mg/kg) ALBENZA to 3 fasted and 2 fed pediatric patients with hydatid <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> disease (age range 6 to 13 years), albendazole sulfoxide pharmacokinetics were similar to those observed in fed adults.</p>
<p><span class="Bold"><span class="Italics">Geriatrics</span></span></p>
<p>Although no studies have investigated the effect of age on albendazole sulfoxide pharmacokinetics, data in 26 hydatid <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> patients (up to 79 years) suggest pharmacokinetics similar to those in young healthy subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4ab605ca-efc8-41e9-9875-d60c743af9ee"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First"><span class="Bold"><span class="Italics">Mechanism of Action</span></span></p>
<p>ALBENZA binds to the colchicine-sensitive site of Î²-tubulin inhibiting their polymerization into microtubules. The decrease in microtubules in the intestinal cells of the parasites decreases their absorptive function, especially the uptake of glucose by the adult and larval forms of the parasites, and also depletes glycogen storage. Insufficient glucose results in insufficient energy for the production of adenosine trisphosphate (ATP) and the parasite eventually dies.</p>
<p><span class="Bold"><span class="Italics">Mechanism of Resistance</span></span></p>
<p>Parasitic resistance to albendazole is caused by changes in amino acids that result in changes in the Î²-tubulin protein. This causes reduced binding of the drug to Î²-tubulin.</p>
<p>In the specified treatment indications albendazole appears to be active against the larval forms of the following organisms:</p>
<p><span class="Italics">Echinococcus granulosus</span></p>
<p><span class="Italics">Taenia solium</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_0af9e6d9-9898-4f4f-a601-9dce763f44f6"></a><a name="section-12"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_de31b5c9-76fe-4247-a4cd-6f7c3a7988be"></a><a name="section-12.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term carcinogenicity studies were conducted in mice and rats.</p>
<p>No evidence of increased incidence of tumors was found in the mice or rats at up to 400 mg/kg/day or 20 mg/kg/day respectively (2 times and 0.2 times the recommended human dose on a body surface area basis).</p>
<p>In genotoxicity tests, albendazole was found negative in an Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span>/Microsome Plate mutation assay, Chinese Hamster Ovary chromosomal aberration test, and <span class="Italics">in vivo</span> mouse micronucleus test. In the <span class="Italics"> in vitro</span> BALB/3T3 cells transformation assay, albendazole produced weak activity in the presence of metabolic activation while no activity was found in the absence of metabolic activation.</p>
<p>Albendazole did not adversely affect male or female fertility in the rat at an oral dose of 30 mg/kg/day (0.32 times the recommended human dose based on body surface area in mg/m<span class="Sup">2</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_d646b22d-76bf-4695-884f-697aacad3ba3"></a><a name="section-13"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_704606fa-4921-44df-8f18-251edc1a3e3e"></a><a name="section-13.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First"><span class="Bold">Tablets</span></p>
<p>Each white to off-white, circular, biconvex, bevel-edged film coated, TILTAB tablet is debossed with â€œapâ€? and â€œ550â€? and contains 200 mg of albendazole.</p>
<p>Bottles of 2 Tablets Â Â Â Â Â Â NDC 52054-550-22</p>
<p>Bottles of 28 Tablets Â Â Â Â NDC 52054-550-28</p>
<p><span class="Bold">Chewable Tablets</span></p>
<p>Each round, mottled pink, concave chewable tablet is debossed with â€œapâ€? above â€œ551â€? and contains 200 mg of albendazole.</p>
<p>2 Tablets in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack (configured as a Wallet Card) Â Â NDC 52054-551-22</p>
<p>6 Tablets in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack; 2 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Packs in 1 Carton  Â Â Â Â Â NDC 52054-551-12</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="LINK_96df9732-76c2-40b9-a382-6bf146dd6b44"></a><a name="section-13.2"></a><p></p>
<h2>16.2 Storage and Handling</h2>
<p class="First">Store at 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_d69590c2-f522-4e66-86ec-e69556c4467a"></a><a name="section-14"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients should be advised that:</p>
<ul class="Disk">
<li>Some people, particularly children, may experience difficulties swallowing the ALBENZA tablets whole. ALBENZA chewable tablet is available for children and patients who may be unable to swallow a tablet.</li>
<li>Take ALBENZA with food.</li>
<li>ALBENZA may cause fetal harm, therefore, obtain a pregnancy test in women of reproductive potential prior to initiating therapy.</li>
<li>Advise women of reproductive potential to use effective birth control while on ALBENZA and for one month after completing treatment.</li>
<li>During ALBENZA therapy, monitor blood counts and liver enzymes every 2 weeks because of the possibility of harm to the liver or bone marrow.</li>
</ul>
<p>ALBENZA and TILTAB are registered trademarks of GlaxoSmithKline, used with permission.</p>
<p>Distributed by:</p>
<p>Amedra Pharmaceuticals LLC<br> Horsham, PA  19044</p>
<p>LB# 799-04</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_0b2067c9-acc6-47ca-b913-d1cebefdfa0c"></a><a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - NDC: 52054-550-22 - 200 mg 2-count Bottle Label</h1>
<div class="Figure"><img alt="Albenza 2 count" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e8941166-b77d-45aa-a6e8-04f1c0afd845&amp;name=albenza-tablets-2.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_188857a1-06a2-4f3b-a022-f8fbe657f476"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - NDC: 52054-550-28 - 200 mg 28-count Bottle Label</h1>
<div class="Figure"><img alt="Albenza 28 count" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e8941166-b77d-45aa-a6e8-04f1c0afd845&amp;name=albenza-tablets-3.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_f5e75e34-9c20-4833-bb2b-9a4622f926a2"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - NDC: 52054-551-22 - 200 mg Wallet Card (Front)</h1>
<div class="Figure"><img alt="Albenza 2 count (Front)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e8941166-b77d-45aa-a6e8-04f1c0afd845&amp;name=albenza-tablets-4.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_1901d40e-fb41-4633-99bc-81f85ee76260"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - NDC: 52054-551-22 - 200 mg Wallet Card (Back)</h1>
<div class="Figure"><img alt="Albenza 2 count (Back)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e8941166-b77d-45aa-a6e8-04f1c0afd845&amp;name=albenza-tablets-5.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALBENZAÂ 		
					</strong><br><span class="contentTableReg">albendazole tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52054-550</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALBENDAZOLE</strong> (ALBENDAZOLE) </td>
<td class="formItem">ALBENDAZOLE</td>
<td class="formItem">200Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SACCHARIN SODIUM MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (cirular) </td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ap;550</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52054-550-22</td>
<td class="formItem">2  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:52054-550-28</td>
<td class="formItem">28  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020666</td>
<td class="formItem">06/11/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALBENZAÂ 		
					</strong><br><span class="contentTableReg">albendazole tablet, chewable</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52054-551</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALBENDAZOLE</strong> (ALBENDAZOLE) </td>
<td class="formItem">ALBENDAZOLE</td>
<td class="formItem">200Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE (19 MPA.S AT 5%)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYVINYL ACETATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCRALOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C RED NO. 30</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">BERRY (wild berry) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ap;551</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52054-551-22</td>
<td class="formItem">2  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA207844</td>
<td class="formItem">09/03/2015</td>
<td class="formItem">09/03/2015</td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Amedra Pharmaceuticals LLC
							(961668824)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cf83e8d6-1685-4c0a-9555-d4d19ff2bf71</div>
<div>Set id: e8941166-b77d-45aa-a6e8-04f1c0afd845</div>
<div>Version: 8</div>
<div>Effective Time: 20150618</div>
</div>
</div>Â <div class="DistributorName">Amedra Pharmaceuticals LLC</div></p>
</body></html>
<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ALBENZA- albendazoleÂ tablet, film coatedÂ </strong><br><strong>ALBENZA- albendazoleÂ tablet, chewableÂ </strong><br>Amedra Pharmaceuticals LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer"><span class="Bold">These highlights do not include all the information needed to use ALBENZA<span class="Sup">Â®</span> safely and effectively.  See full prescribing information for ALBENZA.
			<br><br>ALBENZA<span class="Sup">Â®</span> (albendazole) tablets, for oral use  
			<br>ALBENZA<span class="Sup">Â®</span> (albendazole) chewable tablets, for oral use
			<br>Initial U.S. Approval: 1996
		</span></div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ALBENZA is an anthelmintic drug indicated for: </p>
<ul class="Disk">
<li>Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, <span class="Italics">Taenia solium</span>. (<a href="#LINK_bc09d56e-49b3-41f2-b679-751fb8094bf1">1.1</a>)</li>
<li>Treatment of cystic <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">hydatid disease</span> of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, <span class="Italics">Echinococcus granulosus</span>. (<a href="#LINK_9accd0fb-41e4-4259-8934-ed4ff67fe471">1.2</a>)</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Patients weighing 60 kg or greater, 400 mg twice daily; less than 60 kg, 15 mg/kg/day in divided doses twice daily (maximum total daily dose 800 mg). ALBENZA tablets and ALBENZA chewable tablets should be taken with food. (<a href="#LINK_14fb8aec-ca8c-4877-8b65-9ef7040a4362">2</a>) </p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">Hydatid disease</span>: 28-day cycle followed by 14-day albendazole-free interval for a total of 3 cycles. (<a href="#LINK_14fb8aec-ca8c-4877-8b65-9ef7040a4362">2</a>)</li>
<li>Neurocysticercosis: 8 to 30 days. (<a href="#LINK_14fb8aec-ca8c-4877-8b65-9ef7040a4362">2</a>)</li>
</ul>
<p class="Highlighta">See additional important information in the Full Prescribing Information. (<a href="#LINK_14fb8aec-ca8c-4877-8b65-9ef7040a4362">2</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disk">
<li>Tablet: 200 mg (<a href="#LINK_673a4bdc-62fe-49ba-8bca-fca714b1d1d8">3</a>)</li>
<li>Chewable Tablet: 200 mg (<a href="#LINK_673a4bdc-62fe-49ba-8bca-fca714b1d1d8">3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the benzimidazole class of compounds or any components of ALBENZA.   (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk">
<li>Bone Marrow Suppression: Fatalities have been reported due to bone marrow suppression; monitor blood counts in all patients at the beginning of each 28-day cycle of therapy, and every 2 weeks while on therapy. Discontinue ALBENZA if clinically significant changes in blood counts occur. (<a href="#LINK_8df6476b-155c-4fd9-b2ca-702f67f3665c">5.1</a>, <a href="#LINK_7f9f7ddb-9b74-4388-9f8e-377453f7a240">5.4</a>)</li>
<li>Teratogenic Effects: Obtain pregnancy test in women of reproductive potential prior to therapy and avoid usage in pregnant women except in clinical circumstances where no alternative management is appropriate. Discontinue therapy if pregnancy occurs and apprise patient of potential hazard to the fetus. (<a href="#LINK_e942328f-1ed8-4f31-b6c7-91030be265c8">5.2</a>)</li>
<li>Risk of <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic Symptoms</span>: Neurocysticercosis patients may experience cerebral <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">hypertensive episodes</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (<a href="#LINK_84f94a89-b2ce-4a57-8df2-a8658cb646b5">5.3</a>)</li>
<li>Risk of <span class="product-label-link" type="condition" conceptid="4188175" conceptname="Retinal damage">Retinal Damage</span> in Retinal <span class="product-label-link" type="condition" conceptid="201511" conceptname="Taenia saginata infection">Cysticercosis</span>: Cases of retinal involvement have been reported; examine the patient for the presence of retinal lesions before initiating therapy for neurocysticercosis. (<a href="#LINK_7f9f7ddb-9b74-4388-9f8e-377453f7a240">5.4</a>)</li>
<li>Hepatic Effects. Elevations of liver enzymes may occur. Monitor liver enzymes before the start of each treatment cycle and at least every 2 weeks while on ALBENZA therapy and discontinue if clinically significant elevations occur. (<a href="#LINK_3dcc9482-9a1c-4d3e-a6f1-4325e5e70732">5.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disk">
<li>Adverse reactions 1% or greater in <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">hydatid disease</span>: <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, reversible <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>/<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. (<a href="#LINK_d9044c5b-d44c-4acb-8fd7-9e584bc6fdb4">6.1</a>)</li>
<li>Adverse reactions 1% or greater in neurocysticercosis: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, raised intracranial pressure, meningeal signs. (<a href="#LINK_d9044c5b-d44c-4acb-8fd7-9e584bc6fdb4">6.1</a>)</li>
</ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Amedra Pharmaceuticals LLC at 1-888-894-6528 or FDA at 1-800-FDA-1088 or <span class="Italics"><span class="Underline">www.fda.gov/medwatch</span></span>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disk">
<li>Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when dexamethasone was coadministered with each dose of albendazole. (<a href="#LINK_53d73faf-5231-4db0-b24a-9ea76062c6d9">7.1</a>)</li>
<li>Praziquantel: In the fed state increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects. (<a href="#LINK_2994316b-8499-4d11-bed3-25eee73d2615">7.2</a>)</li>
<li>Cimetidine: Increased albendazole sulfoxide concentrations in bile and cystic fluid by about 2-fold in hydatid <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> patients. (<a href="#LINK_e61c6481-944c-40b6-9a7b-4598ab06b901">7.3</a>)</li>
<li>Theophylline: Albendazole induces cytochrome P450 1A in human <span class="product-label-link" type="condition" conceptid="4101758" conceptname="Hepatocellular carcinoma">hepatoma</span> cells; therefore, it is recommended that plasma concentrations of theophylline be monitored during and after treatment. (<a href="#LINK_3dcc9482-9a1c-4d3e-a6f1-4325e5e70732">5.5</a>, <a href="#LINK_55d1fb61-270e-4a34-a7cc-f6d5e694cf59">7.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 6/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Neurocysticercosis</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">Hydatid Disease</span></a></h2>
<h1><a href="#section-2" class="toc">2  DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosage</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Concomitant Medication to Avoid Adverse Reactions</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Monitoring for Safety Before and During Treatment</a></h2>
<h1><a href="#section-3" class="toc">3  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5  WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Bone Marrow Suppression</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Teratogenic Effects</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Risk of <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic Symptoms</span> in Neurocysticercosis</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Risk of <span class="product-label-link" type="condition" conceptid="4188175" conceptname="Retinal damage">Retinal Damage</span> in Patients with Retinal Neurocysticercosis</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Hepatic Effects</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Unmasking of Neurocysticercosis in Hydatid Patients</a></h2>
<h1><a href="#section-6" class="toc">6  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7  DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Dexamethasone</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Praziquantel</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Cimetidine</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Theophylline</a></h2>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1  Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4  Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5  Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 Patients with Extra-Hepatic Obstruction</a></h2>
<h1><a href="#section-9" class="toc">10  OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11  DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12  CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3  Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13  NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-13.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-13.2" class="toc">16.2 Storage and Handling</a></h2>
<h1><a href="#section-14" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_a091c424-131b-437a-a221-3339fe820d2c"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_bc09d56e-49b3-41f2-b679-751fb8094bf1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Neurocysticercosis</h2>
<p class="First">ALBENZA is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, <span class="Italics">Taenia solium</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9accd0fb-41e4-4259-8934-ed4ff67fe471"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">Hydatid Disease</span></h2>
<p class="First">ALBENZA is indicated for the treatment of cystic <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">hydatid disease</span> of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, <span class="Italics">Echinococcus granulosus</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_14fb8aec-ca8c-4877-8b65-9ef7040a4362"></a><a name="section-2"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_126079a4-1152-434c-99d8-60f82af111f8"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosage</h2>
<p class="First">Dosing of ALBENZA will vary depending upon the indication. ALBENZA tablets may be crushed or chewed and swallowed with a drink of water. ALBENZA chewable tablets are also available for children and patients who may experience swallowing difficulties. ALBENZA tablets and ALBENZA chewable tablets should be taken with food [<span class="Italics">see Clinical Pharmacology (<a href="#LINK_67620ac4-8428-47a8-a5b7-2f2aa441f910">12.3</a>)</span>].</p>
<table>
<caption><span>Table 1: ALBENZA Dosage</span></caption>
<col width="25%">
<col width="25%">
<col width="25%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">Â <span class="Bold">Indication</span>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â <span class="Bold">Patient Weight</span>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â <span class="Bold">Dose</span>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â <span class="Bold">Duration</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" rowspan="2" valign="top">Â <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">Hydatid Disease</span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â 60 kg or greater</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â 400 mg twice daily, with meals</td>
<td class="Lrule Rrule Toprule" rowspan="2" valign="top">Â 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â Less than 60 kg</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top">Â Neurocysticercosis</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â 60 kg or greater</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â 400 mg twice daily, with meals</td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2">Â 8 to 30 days</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">Â Less than 60 kg</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a2eaf6fc-9b7f-489b-9a88-f2fbd8ee7bb3"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Concomitant Medication to Avoid Adverse Reactions</h2>
<p class="First">Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy as required. Oral or intravenous corticosteroids should be considered to prevent cerebral <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">hypertensive episodes</span> during the first week of treatment [<span class="Italics">see Warnings and Precautions (<a href="#LINK_84f94a89-b2ce-4a57-8df2-a8658cb646b5">5.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d18363e9-f3b3-4e65-8fbf-5e56dfd8ba0d"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Monitoring for Safety Before and During Treatment</h2>
<ul class="Disk">
<li>Monitor blood counts at the beginning of each 28-day cycle of therapy, and every 2 weeks while on therapy with ALBENZA in all patients [<span class="Italics">see Warnings and Precautions (<a href="#LINK_8df6476b-155c-4fd9-b2ca-702f67f3665c">5.1</a>)</span>].</li>
<li>Monitor liver enzymes (transaminases) at the beginning of each 28-day cycle of therapy, and at least every 2 weeks during treatment with ALBENZA in all patients [<span class="Italics">see Warnings and Precautions (<a href="#LINK_3dcc9482-9a1c-4d3e-a6f1-4325e5e70732">5.5</a>)</span>].</li>
<li>Obtain a pregnancy test in women of reproductive potential prior to therapy [<span class="Italics">see Warnings and Precautions (<a href="#LINK_e942328f-1ed8-4f31-b6c7-91030be265c8">5.2</a>)</span>].</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_673a4bdc-62fe-49ba-8bca-fca714b1d1d8"></a><a name="section-3"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS</h1>
<ul class="Disk">
<li>Tablet: 200 mg</li>
<li>Chewable Tablet: 200 mg</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_e31d0550-9e66-4f57-b0be-57b820b9d5d0"></a><a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<p class="First">ALBENZA is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the benzimidazole class of compounds or any components of ALBENZA.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_aca4b7d5-2458-4752-994e-b4447b1606f2"></a><a name="section-5"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8df6476b-155c-4fd9-b2ca-702f67f3665c"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Bone Marrow Suppression</h2>
<p class="First">Fatalities associated with the use of ALBENZA have been reported due to <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> or <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> ALBENZA may cause bone marrow suppression, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>. Monitor blood counts at the beginning of each 28-day cycle of therapy, and every 2 weeks while on therapy with ALBENZA in all patients. Patients with liver disease and patients with hepatic <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">echinococcosis</span> are at increased risk for bone marrow suppression and warrant more frequent monitoring of blood counts. Discontinue ALBENZA if clinically significant decreases in blood cell counts occur.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_e942328f-1ed8-4f31-b6c7-91030be265c8"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Teratogenic Effects</h2>
<p class="First">ALBENZA may cause fetal harm and should not be used in pregnant women except in clinical circumstances where no alternative management is appropriate. Obtain pregnancy test prior to prescribing ALBENZA to women of reproductive potential. Advise women of reproductive potential to use effective birth control for the duration of ALBENZA therapy and for one month after end of therapy. Immediately discontinue ALBENZA if a patient becomes pregnant and apprise the patient of the potential hazard to the fetus [<span class="Italics">see Use in Specific Populations (<a href="#LINK_150a082c-35da-41c4-84e6-66b42ced3a07">8.1</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_84f94a89-b2ce-4a57-8df2-a8658cb646b5"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Risk of <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic Symptoms</span> in Neurocysticercosis</h2>
<p class="First">Patients being treated for neurocysticercosis should receive steroid and anticonvulsant therapy to prevent neurological symptoms (e.g. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> and focal signs) as a result of an <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammatory reaction</span> caused by <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of the parasite within the brain.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7f9f7ddb-9b74-4388-9f8e-377453f7a240"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Risk of <span class="product-label-link" type="condition" conceptid="4188175" conceptname="Retinal damage">Retinal Damage</span> in Patients with Retinal Neurocysticercosis</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="201511" conceptname="Taenia saginata infection">Cysticercosis</span> may involve the retina. Before initiating therapy for neurocysticercosis, examine the patient for the presence of retinal lesions. If such lesions are visualized, weigh the need for anticysticeral therapy against the possibility of <span class="product-label-link" type="condition" conceptid="4188175" conceptname="Retinal damage">retinal damage</span> resulting from inflammatory damage caused by ALBENZA-induced <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of the parasite.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3dcc9482-9a1c-4d3e-a6f1-4325e5e70732"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Hepatic Effects</h2>
<p class="First">In clinical trials, treatment with ALBENZA has been associated with mild to moderate elevations of hepatic enzymes in approximately 16% of patients. These elevations have generally returned to normal upon discontinuation of therapy. There have also been case reports of <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span> of uncertain causality and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> [<span class="Italics">see Adverse Reactions (<a href="#LINK_af91181c-2c03-4281-8c99-2b1d3dfd562b">6</a>)</span>].</p>
<p>Monitor liver enzymes (transaminases) before the start of each treatment cycle and at least every 2 weeks during treatment. If hepatic enzymes exceed twice the upper limit of normal, consideration should be given to discontinuing ALBENZA therapy based on individual patient circumstances. Restarting ALBENZA treatment in patients whose hepatic enzymes have normalized off treatment is an individual decision that should take into account the risk/benefit of further ALBENZA usage. Perform laboratory tests frequently if ALBENZA treatment is restarted.</p>
<p>Patients with elevated liver enzyme test results are at increased risk for hepatotoxicity and bone marrow suppression [<span class="Italics">see Warnings and Precautions (<a href="#LINK_8df6476b-155c-4fd9-b2ca-702f67f3665c">5.1</a>)</span>]. Discontinue therapy if liver enzymes are significantly increased or if clinically significant decreases in blood cell counts occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6a98109e-3ff8-4e9c-a0c9-2a3469b07b73"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Unmasking of Neurocysticercosis in Hydatid Patients</h2>
<p class="First">Undiagnosed neurocysticercosis may be uncovered in patients treated with ALBENZA for other conditions. Patients with epidemiologic factors who are at risk for neurocysticercosis should be evaluated prior to initiation of therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_af91181c-2c03-4281-8c99-2b1d3dfd562b"></a><a name="section-6"></a><p></p>
<h1>6  ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d9044c5b-d44c-4acb-8fd7-9e584bc6fdb4"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The adverse reaction profile of ALBENZA differs between <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">hydatid disease</span> and neurocysticercosis. Adverse reactions occurring with a frequency of 1% or greater in either disease are described in Table 2 below.</p>
<p>These symptoms were usually mild and resolved without treatment. Treatment discontinuations were predominantly due to <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (0.7%) or hepatic abnormalities (3.8% in <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">hydatid disease</span>). The following incidence reflects adverse reactions that were reported to be at least possibly or probably related to ALBENZA.</p>
<table>
<caption><span>Table 2: Adverse Reaction Incidence 1% or Greater in <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">Hydatid Disease</span> and Neurocysticercosis</span></caption>
<col width="34%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule">Â <span class="Bold">Adverse Reaction</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â <span class="Bold"><span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">Hydatid Disease</span></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â <span class="Bold">Neurocysticercosis</span>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="3">Â <span class="Bold">Gastrointestinal</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 6</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 6</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="3">Â <span class="Bold">General disorders and administration site conditions</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 0</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="3">Â <span class="Bold">Investigations</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Elevated Hepatic Enzymes</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 16</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â less than 1</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="3">Â <span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â less than 1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 11</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Meningeal Signs</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 0</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Raised Intracranial Pressure</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 0</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â less than 1</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="3">Â <span class="Bold">Skin and subcutaneous tissue disorders</span>
</td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule">Â Reversible <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 2</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â less than 1</td>
</tr>
</tbody>
</table>
<p>The following adverse events were observed at an incidence of less than 1%:</p>
<p><span class="Bold">Blood and Lymphatic System Disorders:</span> There have been reports of <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> [<span class="Italics">see Warnings and Precautions (<a href="#LINK_8df6476b-155c-4fd9-b2ca-702f67f3665c">5.1</a>)</span>].</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d50960c0-2214-4be6-84d4-2a552809af8b"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of ALBENZA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Bold">Blood and Lymphatic System Disorders:</span> <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic anemia</span>, bone marrow suppression, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>.</p>
<p><span class="Bold">General System Disorders:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>.</p>
<p><span class="Bold">Hepatobiliary Disorders:</span> Elevations of hepatic enzymes, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span>.</p>
<p><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>.</p>
<p><span class="Bold">Renal and Urinary Disorders:</span> <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span>.</p>
<p><span class="Bold">Skin and Subcutaneous Tissue Disorders:</span> <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_fa8f9806-4a9d-49b0-bc51-08602f9af925"></a><a name="section-7"></a><p></p>
<h1>7  DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_53d73faf-5231-4db0-b24a-9ea76062c6d9"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Dexamethasone</h2>
<p class="First">Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was co-administered with each dose of albendazole (15 mg/kg/day) in 8 neurocysticercosis patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2994316b-8499-4d11-bed3-25eee73d2615"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Praziquantel</h2>
<p class="First">In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n = 10) compared with a separate group of subjects (n = 6) given albendazole alone. Mean T<span class="Sub">max</span> and mean plasma elimination half-life of albendazole sulfoxide were unchanged. The pharmacokinetics of praziquantel were unchanged following co-administration with albendazole (400 mg).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e61c6481-944c-40b6-9a7b-4598ab06b901"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Cimetidine</h2>
<p class="First">Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> patients treated with cimetidine (10 mg/kg/day) (n = 7) compared with albendazole (20 mg/kg/day) alone (n = 12). Albendazole sulfoxide plasma concentrations were unchanged 4 hours after dosing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_55d1fb61-270e-4a34-a7cc-f6d5e694cf59"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Theophylline</h2>
<p class="First">Following a single dose of albendazole (400 mg), the pharmacokinetics of theophylline (aminophylline 5.8 mg/kg infused over 20 minutes) were unchanged. Albendazole induces cytochrome P450 1A in human <span class="product-label-link" type="condition" conceptid="4101758" conceptname="Hepatocellular carcinoma">hepatoma</span> cells; therefore, it is recommended that plasma concentrations of theophylline be monitored during and after treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_e5741945-51db-4516-be4a-8f7d31a66156"></a><a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_150a082c-35da-41c4-84e6-66b42ced3a07"></a><a name="section-8.1"></a><p></p>
<h2>8.1  Pregnancy</h2>
<p class="First">Pregnancy Category C.</p>
<p>There are no adequate and well-controlled studies of ALBENZA administration in pregnant women. ALBENZA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>ALBENZA should not be used in pregnant women except in clinical circumstances where no alternative management is appropriate. Obtain pregnancy test prior to prescribing ALBENZA to women of reproductive potential. Advise women of reproductive potential to use effective birth control for the duration of ALBENZA therapy and for one month after end of therapy. If a patient becomes pregnant while taking this drug, ALBENZA should be discontinued immediately. If pregnancy occurs while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
<p>ALBENZA has been shown to be teratogenic (to cause embryotoxicity and skeletal malformations) in pregnant rats and rabbits. The teratogenic response in the rat was shown at oral doses of 10 and 30 mg/kg/day (0.10 times and 0.32 times the recommended human dose based on body surface area in mg/m<span class="Sup">2</span>, respectively) during gestation days 6 to 15 and in pregnant rabbits at oral doses of 30 mg/kg/day (0.60 times the recommended human dose based on body surface area in mg/m<span class="Sup">2</span>) administered during gestation days 7 to 19. In the rabbit study, maternal toxicity (33% mortality) was noted at 30 mg/kg/day. In mice, no teratogenic effects were observed at oral doses up to 30 mg/kg/day (0.16 times the recommended human dose based on body surface area in mg/m<span class="Sup">2</span>), administered during gestation days 6 to 15.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_5d659832-f622-4723-ba6a-dec339ba9efd"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">ALBENZA is excreted in animal milk. It is not known whether it is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ALBENZA is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_348a0626-6db1-412a-b13a-c3532570cae1"></a><a name="section-8.3"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">Hydatid disease</span> is uncommon in infants and young children. In neurocysticercosis, the efficacy of ALBENZA in children appears to be similar to that in adults.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_afafad40-1186-42f6-966c-33cddef14250"></a><a name="section-8.4"></a><p></p>
<h2>8.5  Geriatric Use</h2>
<p class="First">In patients aged 65 and older with either <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">hydatid disease</span> or neurocysticercosis, there was insufficient data to determine whether the safety and effectiveness of ALBENZA is different from that of younger patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2f859a28-4c2a-425f-9592-159fbd2104d1"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">The pharmacokinetics of ALBENZA in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> has not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ec1108e8-e16d-49e4-973c-e03fb2b7fdf0"></a><a name="section-8.6"></a><p></p>
<h2>8.7 Patients with Extra-Hepatic Obstruction</h2>
<p class="First">In patients with evidence of extrahepatic obstruction (n = 5), the systemic availability of albendazole sulfoxide was increased, as indicated by a 2-fold increase in maximum serum concentration and a 7-fold increase in area under the curve. The rate of absorption/conversion and elimination of albendazole sulfoxide appeared to be prolonged with mean T<span class="Sub">max</span> and serum elimination half-life values of 10 hours and 31.7 hours, respectively. Plasma concentrations of parent ALBENZA were measurable in only 1 of 5 patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_71332cbf-35dc-4404-a378-b024a139743d"></a><a name="section-9"></a><p></p>
<h1>10  OVERDOSAGE</h1>
<p class="First">In case of overdosage, symptomatic therapy and general supportive measures are recommended.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_9dd9b620-b316-4bed-aeca-fcc0daee9afe"></a><a name="section-10"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First">ALBENZA (albendazole) is an orally administered anthelmintic drug. Chemically, it is methyl 5-(propylthio)-2-benzimidazolecarbamate. Its molecular formula is C<span class="Sub">12</span>H<span class="Sub">15</span>N<span class="Sub">3</span>O<span class="Sub">2</span>S. Its molecular weight is 265.34. It has the following chemical structure:</p>
<div class="Figure"><img alt="methyl 5-(propylthio)-2-benzimidazolecarbamate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e8941166-b77d-45aa-a6e8-04f1c0afd845&amp;name=albenza-tablets-1.jpg"></div>
<p>Albendazole is a white to yellowish powder. It is freely soluble in anhydrous formic acid and very slightly soluble in ether and in methylene chloride. Albendazole is practically insoluble in alcohol and in water.</p>
<p><span class="Bold">Tablets</span></p>
<p>Each white to off-white, circular, biconvex, bevel-edged film coated, TILTAB tablet is debossed with â€œapâ€? and â€œ550â€? and contains 200 mg of albendazole.</p>
<p>Inactive ingredients consist of: carnauba wax, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, sodium lauryl sulfate, sodium saccharin, sodium starch glycolate, and starch.</p>
<p><span class="Bold">Chewable Tablets</span></p>
<p>Each round, mottled pink, concave chewable tablet is debossed with â€œapâ€? above â€œ551â€? and contains 200 mg of albendazole.</p>
<p>Inactive ingredients consist of: lactose monohydrate, microcrystalline cellulose, D-mannitol, sodium starch glycolate, povidone, N-C Wild Berry Type Flavor, magnesium stearate, crospovidone, polyvinyl acetate, sucralose, colloidal silicone dioxide, sodium lauryl sulfate, D&amp;C Red #30/Helendon Pink Aluminum Lake.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_da3bfc87-2e05-4d75-a0a7-0becc600fed1"></a><a name="section-11"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_0b5ed440-1bc7-4b36-a291-6300191f6ec4"></a><a name="section-11.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First">ALBENZA (albendazole) is a synthetic, antihelminthic drug of the class benzimidazole [<span class="Italics">see Clinical Pharmacology (<a href="#LINK_4ab605ca-efc8-41e9-9875-d60c743af9ee">12.4</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_67620ac4-8428-47a8-a5b7-2f2aa441f910"></a><a name="section-11.2"></a><p></p>
<h2>12.3  Pharmacokinetics</h2>
<p class="First"><span class="Bold"><span class="Italics">Absorption</span></span></p>
<p>Albendazole is poorly absorbed from the gastrointestinal tract due to its low aqueous solubility. Albendazole concentrations are negligible or undetectable in plasma as it is rapidly converted to the sulfoxide metabolite prior to reaching the systemic circulation. The systemic anthelmintic activity has been attributed to the primary metabolite, albendazole sulfoxide. Oral bioavailability appears to be enhanced when albendazole is coadministered with a fatty meal (estimated fat content 40 grams) as evidenced by higher (up to 5-fold on average) plasma concentrations of albendazole sulfoxide as compared to the fasted state.</p>
<p>Maximal plasma concentrations of albendazole sulfoxide were achieved 2 hours to 5 hours after dosing and were on average 1310 ng/mL (range 460 ng/mL to 1580 ng/mL) following oral doses of albendazole (400 mg) in 6 <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">hydatid disease</span> patients, when administered with a fatty meal. Plasma concentrations of albendazole sulfoxide increased in a dose-proportional manner over the therapeutic dose range following ingestion of a high-fat meal (fat content 43.1 grams). The mean apparent terminal elimination half-life of albendazole sulfoxide ranged from 8 hours to 12 hours in 25 healthy subjects, as well as in 14 hydatid and 8 neurocysticercosis patients.</p>
<p>In a study conducted in 113 fed and 117 fasted healthy subjects, ALBENZA chewable tablets were bioequivalent to ALBENZA tablets following single 400 mg oral doses of albendazole. In this study, the average time to reach the maximal plasma concentrations of albendazole sulfoxide was 4.5 hours (range 2 to 10 hours) with a fatty meal (fat content 60 grams) and at 3 hours (range 1 to 5 hours) in the fasted state. Following administration of ALBENZA chewable tablets, average maximal plasma concentrations of albendazole sulfoxide  were 804 ng/mL (range 202 to 2244 ng/mL) and 218 ng/mL (range 54 to 592 ng/mL) in the fed and fasted states, respectively. The apparent elimination half-life of albendazole sulfoxide was comparable between ALBENZA chewable tablets and ALBENZA tablets when both were given either under fed or fasted conditions.</p>
<p>Following 4 weeks of treatment with albendazole (200 mg three times daily), 12 patientsâ€™ plasma concentrations of albendazole sulfoxide were approximately 20% lower than those observed during the first half of the treatment period, suggesting that albendazole may induce its own metabolism.</p>
<p><span class="Bold"><span class="Italics">Distribution</span></span></p>
<p>Albendazole sulfoxide is 70% bound to plasma protein and is widely distributed throughout the body; it has been detected in urine, bile, liver, <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> wall, <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> fluid, and cerebrospinal fluid (CSF). Concentrations in plasma were 3-fold to 10-fold and 2-fold to 4-fold higher than those simultaneously determined in <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> fluid and CSF, respectively.</p>
<p><span class="Bold"><span class="Italics">Metabolism and Excretion</span></span></p>
<p>Albendazole is rapidly converted in the liver to the primary metabolite, albendazole sulfoxide, which is further metabolized to albendazole sulfone and other primary oxidative metabolites that have been identified in human urine. Following oral administration, albendazole has not been detected in human urine. Urinary excretion of albendazole sulfoxide is a minor elimination pathway with less than 1% of the dose recovered in the urine. Biliary elimination presumably accounts for a portion of the elimination as evidenced by biliary concentrations of albendazole sulfoxide similar to those achieved in plasma.</p>
<p><span class="Bold"><span class="Italics">Specific Populations</span></span></p>
<p><span class="Bold"><span class="Italics">Pediatrics</span></span></p>
<p>Following single-dose administration of 200 mg to 300 mg (approximately 10 mg/kg) ALBENZA to 3 fasted and 2 fed pediatric patients with hydatid <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> disease (age range 6 to 13 years), albendazole sulfoxide pharmacokinetics were similar to those observed in fed adults.</p>
<p><span class="Bold"><span class="Italics">Geriatrics</span></span></p>
<p>Although no studies have investigated the effect of age on albendazole sulfoxide pharmacokinetics, data in 26 hydatid <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> patients (up to 79 years) suggest pharmacokinetics similar to those in young healthy subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4ab605ca-efc8-41e9-9875-d60c743af9ee"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First"><span class="Bold"><span class="Italics">Mechanism of Action</span></span></p>
<p>ALBENZA binds to the colchicine-sensitive site of Î²-tubulin inhibiting their polymerization into microtubules. The decrease in microtubules in the intestinal cells of the parasites decreases their absorptive function, especially the uptake of glucose by the adult and larval forms of the parasites, and also depletes glycogen storage. Insufficient glucose results in insufficient energy for the production of adenosine trisphosphate (ATP) and the parasite eventually dies.</p>
<p><span class="Bold"><span class="Italics">Mechanism of Resistance</span></span></p>
<p>Parasitic resistance to albendazole is caused by changes in amino acids that result in changes in the Î²-tubulin protein. This causes reduced binding of the drug to Î²-tubulin.</p>
<p>In the specified treatment indications albendazole appears to be active against the larval forms of the following organisms:</p>
<p><span class="Italics">Echinococcus granulosus</span></p>
<p><span class="Italics">Taenia solium</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_0af9e6d9-9898-4f4f-a601-9dce763f44f6"></a><a name="section-12"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_de31b5c9-76fe-4247-a4cd-6f7c3a7988be"></a><a name="section-12.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term carcinogenicity studies were conducted in mice and rats.</p>
<p>No evidence of increased incidence of tumors was found in the mice or rats at up to 400 mg/kg/day or 20 mg/kg/day respectively (2 times and 0.2 times the recommended human dose on a body surface area basis).</p>
<p>In genotoxicity tests, albendazole was found negative in an Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span>/Microsome Plate mutation assay, Chinese Hamster Ovary chromosomal aberration test, and <span class="Italics">in vivo</span> mouse micronucleus test. In the <span class="Italics"> in vitro</span> BALB/3T3 cells transformation assay, albendazole produced weak activity in the presence of metabolic activation while no activity was found in the absence of metabolic activation.</p>
<p>Albendazole did not adversely affect male or female fertility in the rat at an oral dose of 30 mg/kg/day (0.32 times the recommended human dose based on body surface area in mg/m<span class="Sup">2</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_d646b22d-76bf-4695-884f-697aacad3ba3"></a><a name="section-13"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_704606fa-4921-44df-8f18-251edc1a3e3e"></a><a name="section-13.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First"><span class="Bold">Tablets</span></p>
<p>Each white to off-white, circular, biconvex, bevel-edged film coated, TILTAB tablet is debossed with â€œapâ€? and â€œ550â€? and contains 200 mg of albendazole.</p>
<p>Bottles of 2 Tablets Â Â Â Â Â Â NDC 52054-550-22</p>
<p>Bottles of 28 Tablets Â Â Â Â NDC 52054-550-28</p>
<p><span class="Bold">Chewable Tablets</span></p>
<p>Each round, mottled pink, concave chewable tablet is debossed with â€œapâ€? above â€œ551â€? and contains 200 mg of albendazole.</p>
<p>2 Tablets in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack (configured as a Wallet Card) Â Â NDC 52054-551-22</p>
<p>6 Tablets in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack; 2 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Packs in 1 Carton  Â Â Â Â Â NDC 52054-551-12</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="LINK_96df9732-76c2-40b9-a382-6bf146dd6b44"></a><a name="section-13.2"></a><p></p>
<h2>16.2 Storage and Handling</h2>
<p class="First">Store at 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_d69590c2-f522-4e66-86ec-e69556c4467a"></a><a name="section-14"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients should be advised that:</p>
<ul class="Disk">
<li>Some people, particularly children, may experience difficulties swallowing the ALBENZA tablets whole. ALBENZA chewable tablet is available for children and patients who may be unable to swallow a tablet.</li>
<li>Take ALBENZA with food.</li>
<li>ALBENZA may cause fetal harm, therefore, obtain a pregnancy test in women of reproductive potential prior to initiating therapy.</li>
<li>Advise women of reproductive potential to use effective birth control while on ALBENZA and for one month after completing treatment.</li>
<li>During ALBENZA therapy, monitor blood counts and liver enzymes every 2 weeks because of the possibility of harm to the liver or bone marrow.</li>
</ul>
<p>ALBENZA and TILTAB are registered trademarks of GlaxoSmithKline, used with permission.</p>
<p>Distributed by:</p>
<p>Amedra Pharmaceuticals LLC<br> Horsham, PA  19044</p>
<p>LB# 799-04</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_0b2067c9-acc6-47ca-b913-d1cebefdfa0c"></a><a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - NDC: 52054-550-22 - 200 mg 2-count Bottle Label</h1>
<div class="Figure"><img alt="Albenza 2 count" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e8941166-b77d-45aa-a6e8-04f1c0afd845&amp;name=albenza-tablets-2.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_188857a1-06a2-4f3b-a022-f8fbe657f476"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - NDC: 52054-550-28 - 200 mg 28-count Bottle Label</h1>
<div class="Figure"><img alt="Albenza 28 count" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e8941166-b77d-45aa-a6e8-04f1c0afd845&amp;name=albenza-tablets-3.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_f5e75e34-9c20-4833-bb2b-9a4622f926a2"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - NDC: 52054-551-22 - 200 mg Wallet Card (Front)</h1>
<div class="Figure"><img alt="Albenza 2 count (Front)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e8941166-b77d-45aa-a6e8-04f1c0afd845&amp;name=albenza-tablets-4.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_1901d40e-fb41-4633-99bc-81f85ee76260"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - NDC: 52054-551-22 - 200 mg Wallet Card (Back)</h1>
<div class="Figure"><img alt="Albenza 2 count (Back)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e8941166-b77d-45aa-a6e8-04f1c0afd845&amp;name=albenza-tablets-5.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALBENZAÂ 		
					</strong><br><span class="contentTableReg">albendazole tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52054-550</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALBENDAZOLE</strong> (ALBENDAZOLE) </td>
<td class="formItem">ALBENDAZOLE</td>
<td class="formItem">200Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SACCHARIN SODIUM MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (cirular) </td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ap;550</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52054-550-22</td>
<td class="formItem">2  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:52054-550-28</td>
<td class="formItem">28  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020666</td>
<td class="formItem">06/11/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALBENZAÂ 		
					</strong><br><span class="contentTableReg">albendazole tablet, chewable</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52054-551</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALBENDAZOLE</strong> (ALBENDAZOLE) </td>
<td class="formItem">ALBENDAZOLE</td>
<td class="formItem">200Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE (19 MPA.S AT 5%)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYVINYL ACETATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCRALOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C RED NO. 30</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">BERRY (wild berry) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ap;551</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52054-551-22</td>
<td class="formItem">2  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA207844</td>
<td class="formItem">09/03/2015</td>
<td class="formItem">09/03/2015</td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Amedra Pharmaceuticals LLC
							(961668824)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cf83e8d6-1685-4c0a-9555-d4d19ff2bf71</div>
<div>Set id: e8941166-b77d-45aa-a6e8-04f1c0afd845</div>
<div>Version: 8</div>
<div>Effective Time: 20150618</div>
</div>
</div>Â <div class="DistributorName">Amedra Pharmaceuticals LLC</div></p>
</body></html>
<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ALBENZA- albendazoleÂ tablet, film coatedÂ </strong><br><strong>ALBENZA- albendazoleÂ tablet, chewableÂ </strong><br>Amedra Pharmaceuticals LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer"><span class="Bold">These highlights do not include all the information needed to use ALBENZA<span class="Sup">Â®</span> safely and effectively.  See full prescribing information for ALBENZA.
			<br><br>ALBENZA<span class="Sup">Â®</span> (albendazole) tablets, for oral use  
			<br>ALBENZA<span class="Sup">Â®</span> (albendazole) chewable tablets, for oral use
			<br>Initial U.S. Approval: 1996
		</span></div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ALBENZA is an anthelmintic drug indicated for: </p>
<ul class="Disk">
<li>Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, <span class="Italics">Taenia solium</span>. (<a href="#LINK_bc09d56e-49b3-41f2-b679-751fb8094bf1">1.1</a>)</li>
<li>Treatment of cystic <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">hydatid disease</span> of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, <span class="Italics">Echinococcus granulosus</span>. (<a href="#LINK_9accd0fb-41e4-4259-8934-ed4ff67fe471">1.2</a>)</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Patients weighing 60 kg or greater, 400 mg twice daily; less than 60 kg, 15 mg/kg/day in divided doses twice daily (maximum total daily dose 800 mg). ALBENZA tablets and ALBENZA chewable tablets should be taken with food. (<a href="#LINK_14fb8aec-ca8c-4877-8b65-9ef7040a4362">2</a>) </p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">Hydatid disease</span>: 28-day cycle followed by 14-day albendazole-free interval for a total of 3 cycles. (<a href="#LINK_14fb8aec-ca8c-4877-8b65-9ef7040a4362">2</a>)</li>
<li>Neurocysticercosis: 8 to 30 days. (<a href="#LINK_14fb8aec-ca8c-4877-8b65-9ef7040a4362">2</a>)</li>
</ul>
<p class="Highlighta">See additional important information in the Full Prescribing Information. (<a href="#LINK_14fb8aec-ca8c-4877-8b65-9ef7040a4362">2</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disk">
<li>Tablet: 200 mg (<a href="#LINK_673a4bdc-62fe-49ba-8bca-fca714b1d1d8">3</a>)</li>
<li>Chewable Tablet: 200 mg (<a href="#LINK_673a4bdc-62fe-49ba-8bca-fca714b1d1d8">3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the benzimidazole class of compounds or any components of ALBENZA.   (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk">
<li>Bone Marrow Suppression: Fatalities have been reported due to bone marrow suppression; monitor blood counts in all patients at the beginning of each 28-day cycle of therapy, and every 2 weeks while on therapy. Discontinue ALBENZA if clinically significant changes in blood counts occur. (<a href="#LINK_8df6476b-155c-4fd9-b2ca-702f67f3665c">5.1</a>, <a href="#LINK_7f9f7ddb-9b74-4388-9f8e-377453f7a240">5.4</a>)</li>
<li>Teratogenic Effects: Obtain pregnancy test in women of reproductive potential prior to therapy and avoid usage in pregnant women except in clinical circumstances where no alternative management is appropriate. Discontinue therapy if pregnancy occurs and apprise patient of potential hazard to the fetus. (<a href="#LINK_e942328f-1ed8-4f31-b6c7-91030be265c8">5.2</a>)</li>
<li>Risk of <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic Symptoms</span>: Neurocysticercosis patients may experience cerebral <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">hypertensive episodes</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (<a href="#LINK_84f94a89-b2ce-4a57-8df2-a8658cb646b5">5.3</a>)</li>
<li>Risk of <span class="product-label-link" type="condition" conceptid="4188175" conceptname="Retinal damage">Retinal Damage</span> in Retinal <span class="product-label-link" type="condition" conceptid="201511" conceptname="Taenia saginata infection">Cysticercosis</span>: Cases of retinal involvement have been reported; examine the patient for the presence of retinal lesions before initiating therapy for neurocysticercosis. (<a href="#LINK_7f9f7ddb-9b74-4388-9f8e-377453f7a240">5.4</a>)</li>
<li>Hepatic Effects. Elevations of liver enzymes may occur. Monitor liver enzymes before the start of each treatment cycle and at least every 2 weeks while on ALBENZA therapy and discontinue if clinically significant elevations occur. (<a href="#LINK_3dcc9482-9a1c-4d3e-a6f1-4325e5e70732">5.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disk">
<li>Adverse reactions 1% or greater in <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">hydatid disease</span>: <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, reversible <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>/<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. (<a href="#LINK_d9044c5b-d44c-4acb-8fd7-9e584bc6fdb4">6.1</a>)</li>
<li>Adverse reactions 1% or greater in neurocysticercosis: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, raised intracranial pressure, meningeal signs. (<a href="#LINK_d9044c5b-d44c-4acb-8fd7-9e584bc6fdb4">6.1</a>)</li>
</ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Amedra Pharmaceuticals LLC at 1-888-894-6528 or FDA at 1-800-FDA-1088 or <span class="Italics"><span class="Underline">www.fda.gov/medwatch</span></span>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disk">
<li>Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when dexamethasone was coadministered with each dose of albendazole. (<a href="#LINK_53d73faf-5231-4db0-b24a-9ea76062c6d9">7.1</a>)</li>
<li>Praziquantel: In the fed state increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects. (<a href="#LINK_2994316b-8499-4d11-bed3-25eee73d2615">7.2</a>)</li>
<li>Cimetidine: Increased albendazole sulfoxide concentrations in bile and cystic fluid by about 2-fold in hydatid <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> patients. (<a href="#LINK_e61c6481-944c-40b6-9a7b-4598ab06b901">7.3</a>)</li>
<li>Theophylline: Albendazole induces cytochrome P450 1A in human <span class="product-label-link" type="condition" conceptid="4101758" conceptname="Hepatocellular carcinoma">hepatoma</span> cells; therefore, it is recommended that plasma concentrations of theophylline be monitored during and after treatment. (<a href="#LINK_3dcc9482-9a1c-4d3e-a6f1-4325e5e70732">5.5</a>, <a href="#LINK_55d1fb61-270e-4a34-a7cc-f6d5e694cf59">7.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 6/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Neurocysticercosis</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">Hydatid Disease</span></a></h2>
<h1><a href="#section-2" class="toc">2  DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosage</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Concomitant Medication to Avoid Adverse Reactions</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Monitoring for Safety Before and During Treatment</a></h2>
<h1><a href="#section-3" class="toc">3  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5  WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Bone Marrow Suppression</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Teratogenic Effects</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Risk of <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic Symptoms</span> in Neurocysticercosis</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Risk of <span class="product-label-link" type="condition" conceptid="4188175" conceptname="Retinal damage">Retinal Damage</span> in Patients with Retinal Neurocysticercosis</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Hepatic Effects</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Unmasking of Neurocysticercosis in Hydatid Patients</a></h2>
<h1><a href="#section-6" class="toc">6  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7  DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Dexamethasone</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Praziquantel</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Cimetidine</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Theophylline</a></h2>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1  Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4  Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5  Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 Patients with Extra-Hepatic Obstruction</a></h2>
<h1><a href="#section-9" class="toc">10  OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11  DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12  CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3  Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13  NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-13.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-13.2" class="toc">16.2 Storage and Handling</a></h2>
<h1><a href="#section-14" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_a091c424-131b-437a-a221-3339fe820d2c"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_bc09d56e-49b3-41f2-b679-751fb8094bf1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Neurocysticercosis</h2>
<p class="First">ALBENZA is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, <span class="Italics">Taenia solium</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9accd0fb-41e4-4259-8934-ed4ff67fe471"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">Hydatid Disease</span></h2>
<p class="First">ALBENZA is indicated for the treatment of cystic <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">hydatid disease</span> of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, <span class="Italics">Echinococcus granulosus</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_14fb8aec-ca8c-4877-8b65-9ef7040a4362"></a><a name="section-2"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_126079a4-1152-434c-99d8-60f82af111f8"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosage</h2>
<p class="First">Dosing of ALBENZA will vary depending upon the indication. ALBENZA tablets may be crushed or chewed and swallowed with a drink of water. ALBENZA chewable tablets are also available for children and patients who may experience swallowing difficulties. ALBENZA tablets and ALBENZA chewable tablets should be taken with food [<span class="Italics">see Clinical Pharmacology (<a href="#LINK_67620ac4-8428-47a8-a5b7-2f2aa441f910">12.3</a>)</span>].</p>
<table>
<caption><span>Table 1: ALBENZA Dosage</span></caption>
<col width="25%">
<col width="25%">
<col width="25%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">Â <span class="Bold">Indication</span>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â <span class="Bold">Patient Weight</span>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â <span class="Bold">Dose</span>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â <span class="Bold">Duration</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" rowspan="2" valign="top">Â <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">Hydatid Disease</span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â 60 kg or greater</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â 400 mg twice daily, with meals</td>
<td class="Lrule Rrule Toprule" rowspan="2" valign="top">Â 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â Less than 60 kg</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top">Â Neurocysticercosis</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â 60 kg or greater</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â 400 mg twice daily, with meals</td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2">Â 8 to 30 days</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">Â Less than 60 kg</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a2eaf6fc-9b7f-489b-9a88-f2fbd8ee7bb3"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Concomitant Medication to Avoid Adverse Reactions</h2>
<p class="First">Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy as required. Oral or intravenous corticosteroids should be considered to prevent cerebral <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">hypertensive episodes</span> during the first week of treatment [<span class="Italics">see Warnings and Precautions (<a href="#LINK_84f94a89-b2ce-4a57-8df2-a8658cb646b5">5.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d18363e9-f3b3-4e65-8fbf-5e56dfd8ba0d"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Monitoring for Safety Before and During Treatment</h2>
<ul class="Disk">
<li>Monitor blood counts at the beginning of each 28-day cycle of therapy, and every 2 weeks while on therapy with ALBENZA in all patients [<span class="Italics">see Warnings and Precautions (<a href="#LINK_8df6476b-155c-4fd9-b2ca-702f67f3665c">5.1</a>)</span>].</li>
<li>Monitor liver enzymes (transaminases) at the beginning of each 28-day cycle of therapy, and at least every 2 weeks during treatment with ALBENZA in all patients [<span class="Italics">see Warnings and Precautions (<a href="#LINK_3dcc9482-9a1c-4d3e-a6f1-4325e5e70732">5.5</a>)</span>].</li>
<li>Obtain a pregnancy test in women of reproductive potential prior to therapy [<span class="Italics">see Warnings and Precautions (<a href="#LINK_e942328f-1ed8-4f31-b6c7-91030be265c8">5.2</a>)</span>].</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_673a4bdc-62fe-49ba-8bca-fca714b1d1d8"></a><a name="section-3"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS</h1>
<ul class="Disk">
<li>Tablet: 200 mg</li>
<li>Chewable Tablet: 200 mg</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_e31d0550-9e66-4f57-b0be-57b820b9d5d0"></a><a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<p class="First">ALBENZA is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the benzimidazole class of compounds or any components of ALBENZA.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_aca4b7d5-2458-4752-994e-b4447b1606f2"></a><a name="section-5"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8df6476b-155c-4fd9-b2ca-702f67f3665c"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Bone Marrow Suppression</h2>
<p class="First">Fatalities associated with the use of ALBENZA have been reported due to <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> or <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> ALBENZA may cause bone marrow suppression, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>. Monitor blood counts at the beginning of each 28-day cycle of therapy, and every 2 weeks while on therapy with ALBENZA in all patients. Patients with liver disease and patients with hepatic <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">echinococcosis</span> are at increased risk for bone marrow suppression and warrant more frequent monitoring of blood counts. Discontinue ALBENZA if clinically significant decreases in blood cell counts occur.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_e942328f-1ed8-4f31-b6c7-91030be265c8"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Teratogenic Effects</h2>
<p class="First">ALBENZA may cause fetal harm and should not be used in pregnant women except in clinical circumstances where no alternative management is appropriate. Obtain pregnancy test prior to prescribing ALBENZA to women of reproductive potential. Advise women of reproductive potential to use effective birth control for the duration of ALBENZA therapy and for one month after end of therapy. Immediately discontinue ALBENZA if a patient becomes pregnant and apprise the patient of the potential hazard to the fetus [<span class="Italics">see Use in Specific Populations (<a href="#LINK_150a082c-35da-41c4-84e6-66b42ced3a07">8.1</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_84f94a89-b2ce-4a57-8df2-a8658cb646b5"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Risk of <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic Symptoms</span> in Neurocysticercosis</h2>
<p class="First">Patients being treated for neurocysticercosis should receive steroid and anticonvulsant therapy to prevent neurological symptoms (e.g. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> and focal signs) as a result of an <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammatory reaction</span> caused by <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of the parasite within the brain.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7f9f7ddb-9b74-4388-9f8e-377453f7a240"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Risk of <span class="product-label-link" type="condition" conceptid="4188175" conceptname="Retinal damage">Retinal Damage</span> in Patients with Retinal Neurocysticercosis</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="201511" conceptname="Taenia saginata infection">Cysticercosis</span> may involve the retina. Before initiating therapy for neurocysticercosis, examine the patient for the presence of retinal lesions. If such lesions are visualized, weigh the need for anticysticeral therapy against the possibility of <span class="product-label-link" type="condition" conceptid="4188175" conceptname="Retinal damage">retinal damage</span> resulting from inflammatory damage caused by ALBENZA-induced <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of the parasite.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3dcc9482-9a1c-4d3e-a6f1-4325e5e70732"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Hepatic Effects</h2>
<p class="First">In clinical trials, treatment with ALBENZA has been associated with mild to moderate elevations of hepatic enzymes in approximately 16% of patients. These elevations have generally returned to normal upon discontinuation of therapy. There have also been case reports of <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span> of uncertain causality and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> [<span class="Italics">see Adverse Reactions (<a href="#LINK_af91181c-2c03-4281-8c99-2b1d3dfd562b">6</a>)</span>].</p>
<p>Monitor liver enzymes (transaminases) before the start of each treatment cycle and at least every 2 weeks during treatment. If hepatic enzymes exceed twice the upper limit of normal, consideration should be given to discontinuing ALBENZA therapy based on individual patient circumstances. Restarting ALBENZA treatment in patients whose hepatic enzymes have normalized off treatment is an individual decision that should take into account the risk/benefit of further ALBENZA usage. Perform laboratory tests frequently if ALBENZA treatment is restarted.</p>
<p>Patients with elevated liver enzyme test results are at increased risk for hepatotoxicity and bone marrow suppression [<span class="Italics">see Warnings and Precautions (<a href="#LINK_8df6476b-155c-4fd9-b2ca-702f67f3665c">5.1</a>)</span>]. Discontinue therapy if liver enzymes are significantly increased or if clinically significant decreases in blood cell counts occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6a98109e-3ff8-4e9c-a0c9-2a3469b07b73"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Unmasking of Neurocysticercosis in Hydatid Patients</h2>
<p class="First">Undiagnosed neurocysticercosis may be uncovered in patients treated with ALBENZA for other conditions. Patients with epidemiologic factors who are at risk for neurocysticercosis should be evaluated prior to initiation of therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_af91181c-2c03-4281-8c99-2b1d3dfd562b"></a><a name="section-6"></a><p></p>
<h1>6  ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d9044c5b-d44c-4acb-8fd7-9e584bc6fdb4"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The adverse reaction profile of ALBENZA differs between <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">hydatid disease</span> and neurocysticercosis. Adverse reactions occurring with a frequency of 1% or greater in either disease are described in Table 2 below.</p>
<p>These symptoms were usually mild and resolved without treatment. Treatment discontinuations were predominantly due to <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (0.7%) or hepatic abnormalities (3.8% in <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">hydatid disease</span>). The following incidence reflects adverse reactions that were reported to be at least possibly or probably related to ALBENZA.</p>
<table>
<caption><span>Table 2: Adverse Reaction Incidence 1% or Greater in <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">Hydatid Disease</span> and Neurocysticercosis</span></caption>
<col width="34%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule">Â <span class="Bold">Adverse Reaction</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â <span class="Bold"><span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">Hydatid Disease</span></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â <span class="Bold">Neurocysticercosis</span>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="3">Â <span class="Bold">Gastrointestinal</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 6</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 6</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="3">Â <span class="Bold">General disorders and administration site conditions</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 0</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="3">Â <span class="Bold">Investigations</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Elevated Hepatic Enzymes</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 16</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â less than 1</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="3">Â <span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â less than 1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 11</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Meningeal Signs</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 0</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Raised Intracranial Pressure</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 0</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â less than 1</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="3">Â <span class="Bold">Skin and subcutaneous tissue disorders</span>
</td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule">Â Reversible <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 2</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â less than 1</td>
</tr>
</tbody>
</table>
<p>The following adverse events were observed at an incidence of less than 1%:</p>
<p><span class="Bold">Blood and Lymphatic System Disorders:</span> There have been reports of <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> [<span class="Italics">see Warnings and Precautions (<a href="#LINK_8df6476b-155c-4fd9-b2ca-702f67f3665c">5.1</a>)</span>].</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d50960c0-2214-4be6-84d4-2a552809af8b"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of ALBENZA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Bold">Blood and Lymphatic System Disorders:</span> <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic anemia</span>, bone marrow suppression, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>.</p>
<p><span class="Bold">General System Disorders:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>.</p>
<p><span class="Bold">Hepatobiliary Disorders:</span> Elevations of hepatic enzymes, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span>.</p>
<p><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>.</p>
<p><span class="Bold">Renal and Urinary Disorders:</span> <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span>.</p>
<p><span class="Bold">Skin and Subcutaneous Tissue Disorders:</span> <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_fa8f9806-4a9d-49b0-bc51-08602f9af925"></a><a name="section-7"></a><p></p>
<h1>7  DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_53d73faf-5231-4db0-b24a-9ea76062c6d9"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Dexamethasone</h2>
<p class="First">Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was co-administered with each dose of albendazole (15 mg/kg/day) in 8 neurocysticercosis patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2994316b-8499-4d11-bed3-25eee73d2615"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Praziquantel</h2>
<p class="First">In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n = 10) compared with a separate group of subjects (n = 6) given albendazole alone. Mean T<span class="Sub">max</span> and mean plasma elimination half-life of albendazole sulfoxide were unchanged. The pharmacokinetics of praziquantel were unchanged following co-administration with albendazole (400 mg).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e61c6481-944c-40b6-9a7b-4598ab06b901"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Cimetidine</h2>
<p class="First">Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> patients treated with cimetidine (10 mg/kg/day) (n = 7) compared with albendazole (20 mg/kg/day) alone (n = 12). Albendazole sulfoxide plasma concentrations were unchanged 4 hours after dosing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_55d1fb61-270e-4a34-a7cc-f6d5e694cf59"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Theophylline</h2>
<p class="First">Following a single dose of albendazole (400 mg), the pharmacokinetics of theophylline (aminophylline 5.8 mg/kg infused over 20 minutes) were unchanged. Albendazole induces cytochrome P450 1A in human <span class="product-label-link" type="condition" conceptid="4101758" conceptname="Hepatocellular carcinoma">hepatoma</span> cells; therefore, it is recommended that plasma concentrations of theophylline be monitored during and after treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_e5741945-51db-4516-be4a-8f7d31a66156"></a><a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_150a082c-35da-41c4-84e6-66b42ced3a07"></a><a name="section-8.1"></a><p></p>
<h2>8.1  Pregnancy</h2>
<p class="First">Pregnancy Category C.</p>
<p>There are no adequate and well-controlled studies of ALBENZA administration in pregnant women. ALBENZA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>ALBENZA should not be used in pregnant women except in clinical circumstances where no alternative management is appropriate. Obtain pregnancy test prior to prescribing ALBENZA to women of reproductive potential. Advise women of reproductive potential to use effective birth control for the duration of ALBENZA therapy and for one month after end of therapy. If a patient becomes pregnant while taking this drug, ALBENZA should be discontinued immediately. If pregnancy occurs while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
<p>ALBENZA has been shown to be teratogenic (to cause embryotoxicity and skeletal malformations) in pregnant rats and rabbits. The teratogenic response in the rat was shown at oral doses of 10 and 30 mg/kg/day (0.10 times and 0.32 times the recommended human dose based on body surface area in mg/m<span class="Sup">2</span>, respectively) during gestation days 6 to 15 and in pregnant rabbits at oral doses of 30 mg/kg/day (0.60 times the recommended human dose based on body surface area in mg/m<span class="Sup">2</span>) administered during gestation days 7 to 19. In the rabbit study, maternal toxicity (33% mortality) was noted at 30 mg/kg/day. In mice, no teratogenic effects were observed at oral doses up to 30 mg/kg/day (0.16 times the recommended human dose based on body surface area in mg/m<span class="Sup">2</span>), administered during gestation days 6 to 15.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_5d659832-f622-4723-ba6a-dec339ba9efd"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">ALBENZA is excreted in animal milk. It is not known whether it is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ALBENZA is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_348a0626-6db1-412a-b13a-c3532570cae1"></a><a name="section-8.3"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">Hydatid disease</span> is uncommon in infants and young children. In neurocysticercosis, the efficacy of ALBENZA in children appears to be similar to that in adults.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_afafad40-1186-42f6-966c-33cddef14250"></a><a name="section-8.4"></a><p></p>
<h2>8.5  Geriatric Use</h2>
<p class="First">In patients aged 65 and older with either <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">hydatid disease</span> or neurocysticercosis, there was insufficient data to determine whether the safety and effectiveness of ALBENZA is different from that of younger patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2f859a28-4c2a-425f-9592-159fbd2104d1"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">The pharmacokinetics of ALBENZA in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> has not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ec1108e8-e16d-49e4-973c-e03fb2b7fdf0"></a><a name="section-8.6"></a><p></p>
<h2>8.7 Patients with Extra-Hepatic Obstruction</h2>
<p class="First">In patients with evidence of extrahepatic obstruction (n = 5), the systemic availability of albendazole sulfoxide was increased, as indicated by a 2-fold increase in maximum serum concentration and a 7-fold increase in area under the curve. The rate of absorption/conversion and elimination of albendazole sulfoxide appeared to be prolonged with mean T<span class="Sub">max</span> and serum elimination half-life values of 10 hours and 31.7 hours, respectively. Plasma concentrations of parent ALBENZA were measurable in only 1 of 5 patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_71332cbf-35dc-4404-a378-b024a139743d"></a><a name="section-9"></a><p></p>
<h1>10  OVERDOSAGE</h1>
<p class="First">In case of overdosage, symptomatic therapy and general supportive measures are recommended.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_9dd9b620-b316-4bed-aeca-fcc0daee9afe"></a><a name="section-10"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First">ALBENZA (albendazole) is an orally administered anthelmintic drug. Chemically, it is methyl 5-(propylthio)-2-benzimidazolecarbamate. Its molecular formula is C<span class="Sub">12</span>H<span class="Sub">15</span>N<span class="Sub">3</span>O<span class="Sub">2</span>S. Its molecular weight is 265.34. It has the following chemical structure:</p>
<div class="Figure"><img alt="methyl 5-(propylthio)-2-benzimidazolecarbamate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e8941166-b77d-45aa-a6e8-04f1c0afd845&amp;name=albenza-tablets-1.jpg"></div>
<p>Albendazole is a white to yellowish powder. It is freely soluble in anhydrous formic acid and very slightly soluble in ether and in methylene chloride. Albendazole is practically insoluble in alcohol and in water.</p>
<p><span class="Bold">Tablets</span></p>
<p>Each white to off-white, circular, biconvex, bevel-edged film coated, TILTAB tablet is debossed with â€œapâ€? and â€œ550â€? and contains 200 mg of albendazole.</p>
<p>Inactive ingredients consist of: carnauba wax, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, sodium lauryl sulfate, sodium saccharin, sodium starch glycolate, and starch.</p>
<p><span class="Bold">Chewable Tablets</span></p>
<p>Each round, mottled pink, concave chewable tablet is debossed with â€œapâ€? above â€œ551â€? and contains 200 mg of albendazole.</p>
<p>Inactive ingredients consist of: lactose monohydrate, microcrystalline cellulose, D-mannitol, sodium starch glycolate, povidone, N-C Wild Berry Type Flavor, magnesium stearate, crospovidone, polyvinyl acetate, sucralose, colloidal silicone dioxide, sodium lauryl sulfate, D&amp;C Red #30/Helendon Pink Aluminum Lake.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_da3bfc87-2e05-4d75-a0a7-0becc600fed1"></a><a name="section-11"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_0b5ed440-1bc7-4b36-a291-6300191f6ec4"></a><a name="section-11.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First">ALBENZA (albendazole) is a synthetic, antihelminthic drug of the class benzimidazole [<span class="Italics">see Clinical Pharmacology (<a href="#LINK_4ab605ca-efc8-41e9-9875-d60c743af9ee">12.4</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_67620ac4-8428-47a8-a5b7-2f2aa441f910"></a><a name="section-11.2"></a><p></p>
<h2>12.3  Pharmacokinetics</h2>
<p class="First"><span class="Bold"><span class="Italics">Absorption</span></span></p>
<p>Albendazole is poorly absorbed from the gastrointestinal tract due to its low aqueous solubility. Albendazole concentrations are negligible or undetectable in plasma as it is rapidly converted to the sulfoxide metabolite prior to reaching the systemic circulation. The systemic anthelmintic activity has been attributed to the primary metabolite, albendazole sulfoxide. Oral bioavailability appears to be enhanced when albendazole is coadministered with a fatty meal (estimated fat content 40 grams) as evidenced by higher (up to 5-fold on average) plasma concentrations of albendazole sulfoxide as compared to the fasted state.</p>
<p>Maximal plasma concentrations of albendazole sulfoxide were achieved 2 hours to 5 hours after dosing and were on average 1310 ng/mL (range 460 ng/mL to 1580 ng/mL) following oral doses of albendazole (400 mg) in 6 <span class="product-label-link" type="condition" conceptid="432831" conceptname="Echinococcus granulosus infection">hydatid disease</span> patients, when administered with a fatty meal. Plasma concentrations of albendazole sulfoxide increased in a dose-proportional manner over the therapeutic dose range following ingestion of a high-fat meal (fat content 43.1 grams). The mean apparent terminal elimination half-life of albendazole sulfoxide ranged from 8 hours to 12 hours in 25 healthy subjects, as well as in 14 hydatid and 8 neurocysticercosis patients.</p>
<p>In a study conducted in 113 fed and 117 fasted healthy subjects, ALBENZA chewable tablets were bioequivalent to ALBENZA tablets following single 400 mg oral doses of albendazole. In this study, the average time to reach the maximal plasma concentrations of albendazole sulfoxide was 4.5 hours (range 2 to 10 hours) with a fatty meal (fat content 60 grams) and at 3 hours (range 1 to 5 hours) in the fasted state. Following administration of ALBENZA chewable tablets, average maximal plasma concentrations of albendazole sulfoxide  were 804 ng/mL (range 202 to 2244 ng/mL) and 218 ng/mL (range 54 to 592 ng/mL) in the fed and fasted states, respectively. The apparent elimination half-life of albendazole sulfoxide was comparable between ALBENZA chewable tablets and ALBENZA tablets when both were given either under fed or fasted conditions.</p>
<p>Following 4 weeks of treatment with albendazole (200 mg three times daily), 12 patientsâ€™ plasma concentrations of albendazole sulfoxide were approximately 20% lower than those observed during the first half of the treatment period, suggesting that albendazole may induce its own metabolism.</p>
<p><span class="Bold"><span class="Italics">Distribution</span></span></p>
<p>Albendazole sulfoxide is 70% bound to plasma protein and is widely distributed throughout the body; it has been detected in urine, bile, liver, <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> wall, <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> fluid, and cerebrospinal fluid (CSF). Concentrations in plasma were 3-fold to 10-fold and 2-fold to 4-fold higher than those simultaneously determined in <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> fluid and CSF, respectively.</p>
<p><span class="Bold"><span class="Italics">Metabolism and Excretion</span></span></p>
<p>Albendazole is rapidly converted in the liver to the primary metabolite, albendazole sulfoxide, which is further metabolized to albendazole sulfone and other primary oxidative metabolites that have been identified in human urine. Following oral administration, albendazole has not been detected in human urine. Urinary excretion of albendazole sulfoxide is a minor elimination pathway with less than 1% of the dose recovered in the urine. Biliary elimination presumably accounts for a portion of the elimination as evidenced by biliary concentrations of albendazole sulfoxide similar to those achieved in plasma.</p>
<p><span class="Bold"><span class="Italics">Specific Populations</span></span></p>
<p><span class="Bold"><span class="Italics">Pediatrics</span></span></p>
<p>Following single-dose administration of 200 mg to 300 mg (approximately 10 mg/kg) ALBENZA to 3 fasted and 2 fed pediatric patients with hydatid <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> disease (age range 6 to 13 years), albendazole sulfoxide pharmacokinetics were similar to those observed in fed adults.</p>
<p><span class="Bold"><span class="Italics">Geriatrics</span></span></p>
<p>Although no studies have investigated the effect of age on albendazole sulfoxide pharmacokinetics, data in 26 hydatid <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> patients (up to 79 years) suggest pharmacokinetics similar to those in young healthy subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4ab605ca-efc8-41e9-9875-d60c743af9ee"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First"><span class="Bold"><span class="Italics">Mechanism of Action</span></span></p>
<p>ALBENZA binds to the colchicine-sensitive site of Î²-tubulin inhibiting their polymerization into microtubules. The decrease in microtubules in the intestinal cells of the parasites decreases their absorptive function, especially the uptake of glucose by the adult and larval forms of the parasites, and also depletes glycogen storage. Insufficient glucose results in insufficient energy for the production of adenosine trisphosphate (ATP) and the parasite eventually dies.</p>
<p><span class="Bold"><span class="Italics">Mechanism of Resistance</span></span></p>
<p>Parasitic resistance to albendazole is caused by changes in amino acids that result in changes in the Î²-tubulin protein. This causes reduced binding of the drug to Î²-tubulin.</p>
<p>In the specified treatment indications albendazole appears to be active against the larval forms of the following organisms:</p>
<p><span class="Italics">Echinococcus granulosus</span></p>
<p><span class="Italics">Taenia solium</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_0af9e6d9-9898-4f4f-a601-9dce763f44f6"></a><a name="section-12"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_de31b5c9-76fe-4247-a4cd-6f7c3a7988be"></a><a name="section-12.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term carcinogenicity studies were conducted in mice and rats.</p>
<p>No evidence of increased incidence of tumors was found in the mice or rats at up to 400 mg/kg/day or 20 mg/kg/day respectively (2 times and 0.2 times the recommended human dose on a body surface area basis).</p>
<p>In genotoxicity tests, albendazole was found negative in an Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span>/Microsome Plate mutation assay, Chinese Hamster Ovary chromosomal aberration test, and <span class="Italics">in vivo</span> mouse micronucleus test. In the <span class="Italics"> in vitro</span> BALB/3T3 cells transformation assay, albendazole produced weak activity in the presence of metabolic activation while no activity was found in the absence of metabolic activation.</p>
<p>Albendazole did not adversely affect male or female fertility in the rat at an oral dose of 30 mg/kg/day (0.32 times the recommended human dose based on body surface area in mg/m<span class="Sup">2</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_d646b22d-76bf-4695-884f-697aacad3ba3"></a><a name="section-13"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_704606fa-4921-44df-8f18-251edc1a3e3e"></a><a name="section-13.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First"><span class="Bold">Tablets</span></p>
<p>Each white to off-white, circular, biconvex, bevel-edged film coated, TILTAB tablet is debossed with â€œapâ€? and â€œ550â€? and contains 200 mg of albendazole.</p>
<p>Bottles of 2 Tablets Â Â Â Â Â Â NDC 52054-550-22</p>
<p>Bottles of 28 Tablets Â Â Â Â NDC 52054-550-28</p>
<p><span class="Bold">Chewable Tablets</span></p>
<p>Each round, mottled pink, concave chewable tablet is debossed with â€œapâ€? above â€œ551â€? and contains 200 mg of albendazole.</p>
<p>2 Tablets in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack (configured as a Wallet Card) Â Â NDC 52054-551-22</p>
<p>6 Tablets in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack; 2 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Packs in 1 Carton  Â Â Â Â Â NDC 52054-551-12</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="LINK_96df9732-76c2-40b9-a382-6bf146dd6b44"></a><a name="section-13.2"></a><p></p>
<h2>16.2 Storage and Handling</h2>
<p class="First">Store at 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_d69590c2-f522-4e66-86ec-e69556c4467a"></a><a name="section-14"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients should be advised that:</p>
<ul class="Disk">
<li>Some people, particularly children, may experience difficulties swallowing the ALBENZA tablets whole. ALBENZA chewable tablet is available for children and patients who may be unable to swallow a tablet.</li>
<li>Take ALBENZA with food.</li>
<li>ALBENZA may cause fetal harm, therefore, obtain a pregnancy test in women of reproductive potential prior to initiating therapy.</li>
<li>Advise women of reproductive potential to use effective birth control while on ALBENZA and for one month after completing treatment.</li>
<li>During ALBENZA therapy, monitor blood counts and liver enzymes every 2 weeks because of the possibility of harm to the liver or bone marrow.</li>
</ul>
<p>ALBENZA and TILTAB are registered trademarks of GlaxoSmithKline, used with permission.</p>
<p>Distributed by:</p>
<p>Amedra Pharmaceuticals LLC<br> Horsham, PA  19044</p>
<p>LB# 799-04</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_0b2067c9-acc6-47ca-b913-d1cebefdfa0c"></a><a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - NDC: 52054-550-22 - 200 mg 2-count Bottle Label</h1>
<div class="Figure"><img alt="Albenza 2 count" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e8941166-b77d-45aa-a6e8-04f1c0afd845&amp;name=albenza-tablets-2.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_188857a1-06a2-4f3b-a022-f8fbe657f476"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - NDC: 52054-550-28 - 200 mg 28-count Bottle Label</h1>
<div class="Figure"><img alt="Albenza 28 count" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e8941166-b77d-45aa-a6e8-04f1c0afd845&amp;name=albenza-tablets-3.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_f5e75e34-9c20-4833-bb2b-9a4622f926a2"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - NDC: 52054-551-22 - 200 mg Wallet Card (Front)</h1>
<div class="Figure"><img alt="Albenza 2 count (Front)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e8941166-b77d-45aa-a6e8-04f1c0afd845&amp;name=albenza-tablets-4.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_1901d40e-fb41-4633-99bc-81f85ee76260"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - NDC: 52054-551-22 - 200 mg Wallet Card (Back)</h1>
<div class="Figure"><img alt="Albenza 2 count (Back)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e8941166-b77d-45aa-a6e8-04f1c0afd845&amp;name=albenza-tablets-5.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALBENZAÂ 		
					</strong><br><span class="contentTableReg">albendazole tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52054-550</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALBENDAZOLE</strong> (ALBENDAZOLE) </td>
<td class="formItem">ALBENDAZOLE</td>
<td class="formItem">200Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SACCHARIN SODIUM MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (cirular) </td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ap;550</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52054-550-22</td>
<td class="formItem">2  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:52054-550-28</td>
<td class="formItem">28  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020666</td>
<td class="formItem">06/11/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALBENZAÂ 		
					</strong><br><span class="contentTableReg">albendazole tablet, chewable</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52054-551</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALBENDAZOLE</strong> (ALBENDAZOLE) </td>
<td class="formItem">ALBENDAZOLE</td>
<td class="formItem">200Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE (19 MPA.S AT 5%)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYVINYL ACETATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCRALOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C RED NO. 30</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">BERRY (wild berry) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ap;551</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52054-551-22</td>
<td class="formItem">2  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA207844</td>
<td class="formItem">09/03/2015</td>
<td class="formItem">09/03/2015</td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Amedra Pharmaceuticals LLC
							(961668824)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cf83e8d6-1685-4c0a-9555-d4d19ff2bf71</div>
<div>Set id: e8941166-b77d-45aa-a6e8-04f1c0afd845</div>
<div>Version: 8</div>
<div>Effective Time: 20150618</div>
</div>
</div>Â <div class="DistributorName">Amedra Pharmaceuticals LLC</div></p>
</body></html>
